The table below lists pertinent evidence on the clinical effectiveness and safety of some drugs and other therapies being considered for COVID-19. Most authorities recommend use of these drugs only in the setting of a clinical trial or when access via clinical trial is not available. Inclusion in this table is not a recommendation for use for treatment of COVID-19. The information on these drugs is evolving rapidly and The Medical Letter does not warrant that all the material in this publication is current, accurate, or complete in every respect.

<table>
<thead>
<tr>
<th>Drug</th>
<th>Evidence</th>
<th>Use</th>
</tr>
</thead>
<tbody>
<tr>
<td>Remdesivir</td>
<td>Evidence from a randomized controlled trial</td>
<td>Use only in the setting of a clinical trial</td>
</tr>
<tr>
<td>Convalescent Plasma</td>
<td>Evidence from case series and observational studies</td>
<td>Use only in the setting of a clinical trial</td>
</tr>
<tr>
<td>Corticosteroids</td>
<td>Evidence from observational studies</td>
<td>Use only in the setting of a clinical trial</td>
</tr>
</tbody>
</table>

To support more content like this, please consider making a donation* or becoming a subscriber.

The Medical Letter®
Because the source matters.

The Medical Letter is a nonprofit organization* that relies solely on subscription fees and donations to support our mission of providing objective, practical, and timely information on drugs and therapeutics.

Our work relies on support from people like you who value credible, unbiased drug information that is free of any commercial interest.

Subscribe for less than $3/week.

*The Medical Letter is a nonprofit, tax-exempt organization under Section 501(C)(3) of the Internal Revenue Code. Donations are tax-deductible as allowed by law.
## Table of Contents

**INVESTIGATIONAL DRUGS** ................................................................. - 4 -

- Antivirals .......................................................................................... - 4 -
  - FAVIPIRA VIR
  - REMDESIVIR

- Convalescent Plasma ....................................................................... - 11 -
- Intravenous Immune Globulin (IVIG) ............................................... - 14 -
- Monoclonal Antibodies ..................................................................... - 16 -
  - LY-CoV555
  - REGN- COV-2
  - AZD7442

- Glutathione and N-acetylcysteine .................................................. - 18 -
- Stem Cell Therapy ........................................................................... - 19 -

**REPURPOSED DRUGS** ..................................................................... - 21 -

- Corticosteroids (systemic) .............................................................. - 21 -
- Inhaled Corticosteroids .................................................................. - 26 -
- IL-6 Inhibitors ................................................................................ - 27 -
  - SARILUMAB
  - TOCILIZUMAB

- IL-1 Receptor Antagonist ............................................................... - 32 -
  - ANAKINRA

- Janus Kinase (JAK) Inhibitors ........................................................ - 34 -
  - BARICITINIB
  - RUXOLITINIB

- TNF Inhibitors ................................................................................ - 36 -
  - TNF INHIBITORS

- Anti-CD6 Monoclonal Antibody ..................................................... - 37 -
  - ITOLIZUMAB

- Antimalarials .................................................................................. - 38 -

**CHLOROQUINE**

- HYDROXYCHLOROQUINE

- Macrolide Antibiotic ...................................................................... - 54 -
  - AZITHROMYCIN

- HIV Protease Inhibitors ................................................................. - 60 -
  - ATVANAVIR
  - DARUNAVIR/COCICISTAT
  - LOPINAVIR/ RITONAVIR

- Interferon Beta and Ribavirin ....................................................... - 63 -

- Antiparasitic ................................................................................... - 65 -
  - IVERMECTIN

- Bradykinin Inhibitor ...................................................................... - 66 -
  - ICATIBANT

- Colchicine ....................................................................................... - 67 -

- Dipeptidyl Peptidase-4 (DPP-4) Inhibitors .................................... - 68 -

- Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors ............... - 69 -

- H2-Receptor Antagonists (H2RAs) .............................................. - 70 -
  - FAMOTIDINE

- Vitamins ........................................................................................ - 73 -
  - ASCORBIC ACID
  - ZINC
  - VITAMIN D
  - THIAMINE

- Nasal Saline Irrigation .................................................................... - 77 -

- Melatonin ....................................................................................... - 77 -

- Benzalkonium Chloride ............................................................... - 78 -

**CONCOMITANT DRUGS** ................................................................ - 79 -

- Renin-Angiotensin System (RAS) Inhibitors ............................... - 79 -
  - ANGIOITENSIN-CONVERTING ENZYME (ACE) INHIBITORS
  - ANGIOITENSIN RECEPTOR BLOCKERS (ARBS)

- Nonsteroidal Anti-inflammatory Drugs (NSAIDs) ..................... - 85 -

- Proton Pump Inhibitors (PPIs) ..................................................... - 86 -
Biguanide

VACCINES

Adenovirus-Vectored Vaccines

CHIMPANZEE ADENOVIRUS-VECTORED COVID-19 (ChAdOx1 nCoV-19) VACCINE (AZD1222)

RECOMBINANT ADENOVIRUS TYPE-5 (Ad5)-VECTORED COVID-19 VACCINE

ADENOVIRUS SEROTYPE 26 (Ad26) VECTOR-BASED COVID-19 VACCINE (Ad26.COV2.S)

mRNA Vaccines

mRNA-1273

BNT162b1 and BNT162b2

Adjuvanted Recombinant Nanoparticle Vaccine

NVX-CoV2373

Inactivated Vaccine

Whole-Virus Inactivated SARS-CoV-2 Vaccine (WIV04 strain)
<table>
<thead>
<tr>
<th>DRUG AND DOSAGE</th>
<th>EFFICACY</th>
<th>ADVERSE EFFECTS/INTERACTIONS</th>
<th>COMMENTS</th>
</tr>
</thead>
</table>
| **Antivirals** | **Q Cai et al. 2020**<sup>1</sup>  
*Population*: hospitalized, non-severe (n=80)  
*Design*: open-label, non-randomized  
*Results*: shorter viral clearance time (4 vs 11 days) and improvements in chest CT (91.4% vs 62.2%) with favipiravir vs lopinavir/ritonavir; results should be interpreted with caution<sup>1</sup>  
| **Adverse Effects**:  
- Elevated LFTs, diarrhea, nausea, vomiting, chest pain and elevated serum uric acid  
**Drug Interactions**:  
- May increase serum concentrations of some drugs such as acetaminophen, penicillins, tazobactam, repaglinide, pioglitazone and rosiglitazone, oseltamivir, theophylline, and progestins  
| **Not FDA-approved and not available yet in the US**  
**Approved in other countries for treatment of influenza**  
**Russian Ministry of Health granted conditional marketing authorization for favipiravir (Avifavir) (added 8/9/2020)**  
**Viral RNA polymerase inhibitor**  
**Limited data available to date; may be less effective for patients with more severe disease**  
**Randomized controlled trial of favipiravir alone and in combination with tocilizumab ongoing in China**  
**Pregnancy**:  
- Contraindicated for use in pregnant women<sup>4</sup>  
- Teratogenic effects in animal studies  
**Men taking the drug should avoid intercourse with pregnant women during treatment and for at least 7 days after the last dose**  
|  
| **FAVIPIRAVIR – AVIGAN (FUGIFILM)**  
*(updated 9/24/2020)*  
*Dosage*:  
- 1600 mg PO bid on day 1, then 600 mg bid on days 2-7<sup>1</sup>  
- Some suggest a dosage of 2400-3000 mg bid on day 1, then 1200-1800 mg bid<sup>2</sup>  
|  
| **FAVIPIRAVIR – AVIGAN (FUGIFILM)**  
*(updated 9/24/2020)*  
*Dosage*:  
- 1600 mg PO bid on day 1, then 600 mg bid on days 2-7<sup>1</sup>  
- Some suggest a dosage of 2400-3000 mg bid on day 1, then 1200-1800 mg bid<sup>2</sup>  
| **Chen et al. 2020**<sup>3</sup>  
*Population*: hospitalized patients (n=236)  
*Design*: randomized, open-label  
*favipiravir vs arbidol* (an influenza drug not available in the US); both in addition to standard therapy  
*Results*:  
- clinical recovery rate at day 7 was similar for favipiravir and arbidol (51.67% vs 61.21%; p=0.1396)  
- in patients with moderate disease, clinical recovery rates were higher with favipiravir than arbidol (71.43% vs 55.86%; p=0.0199)  
*Limitations*:  
- not peer-reviewed  
|  
| **Ivashchenko et al. Clin Infect Dis 2020**<sup>5</sup> *(added 8/9/2020)*  
*Population*: hospitalized patients with moderate COVID-19 pneumonia in
FAVIPIRAVIR (continued)

Russia; 25% on supplemental oxygen and 75% on ambient air (n=60)

**Design:** adaptive, multicenter, randomized, open-label trial; results from 60 patients in phase II trial presented

- Favipiravir 1600 mg BID on day 1, then 600 mg bid days 2-14, favipiravir 1800 mg BID on day 1, then 800 mg bid days 2-14, or standard of care (75% received hydroxychloroquine or chloroquine)
- Mean 6.7 days from start of symptoms

**Results:**

- Viral clearance (2 negative PCR tests with at least a 24-hour interval) was achieved by day 5 in 62.5% of patients taking favipiravir vs 30.0% of those who received standard of care (p=0.018)
- Viral clearance by day 10 was achieved in 92.5% of favipiravir-treated patients vs 80.0% on standard of care (p=0.155)

**Limitations:** interim results

**Phase 3 Trial 2020** *(added 9/24/2020)*

**Population:** COVID-19 patients with non-severe pneumonia in Japan (n=156)

**Design:** randomized, placebo-controlled, single-blind phase 3 trial

**Results:** recovery time was 11.9 days with favipiravir vs 14.7 days with placebo (p=0.0136)

**Limitations:** preliminary data; trial not yet published

REMDESIVIR – VEKLURY (GILEAD)

(added 9/18/2020)

Dosage:
- Adults ≥40 kg: 200 mg IV on day 1, then 100 mg IV once/day for a total of 5 or 10 days
- Infuse over 30-120 minutes
- In addition to standard care
- Not recommended if eGFR <30 ml/min or ALT >5x ULN
- NIH guidelines recommend a duration of 5 days or until hospital discharge

NIAD. ACTT-1. NEJM 2020* (added 5/4/20; updated 5/25/20)

Population: 1063 hospitalized patients with advanced disease and lung involvement (88.7% had severe disease)

Design:
- randomized, double-blind, placebo-controlled trial in US, Europe and Asia
- 200 mg on day 1, then 100 mg once/day 2-10 or until discharge or death
- median time from symptom onset to randomization was 9 days

Results:
- recovery time 31% shorter with remdesivir (11 days vs 15 days with placebo; p<0.001)
- lower mortality rate at 14 days (7.1% vs 11.9%; not statistically significant)
- effect appeared to be greatest in hospitalized patients requiring oxygen (baseline ordinal score of 5; this category had largest sample size); mortality difference between remdesivir and placebo groups appeared smaller in patients who did not require oxygen (ordinal score of 4) and in those who required mechanical ventilation (ordinal score of 6)

Limitations:
- preliminary report

Adverse Effects:
- Safety not established; additional data needed
- Elevated liver enzymes, hypokalemia, headache, and infusion-related reactions, including hypotension, nausea, vomiting, sweating, and shivering

Drug Interactions: (updated 6/18/2020)
- No human drug trial conducted
- Substrate for CYP2C8, CYP2D6, and CYP3A4, and for Organic Anion Transporting Polypeptides 1B1 (OAPT1B1) and P-glycoprotein (Pgp) transporters in vitro.² Strong inducers of these enzymes/transporters may decrease serum concentrations of remdesivir⁵ and inhibitors of these enzymes/transporters could potentially increase the risk of toxicity such as hepatotoxicity¹⁴
- Inhibitor of CYP3A4, OATP1B1, OATP1B3, BSEP, MRP4, and NTCP.
- Clinical relevance has not been established.

- Broad-spectrum nucleotide analog prodrug that inhibits viral RNA replication by blocking RNA-dependent RNA polymerase
- Has in vivo and in vitro activity against Ebola virus and coronaviruses (MERS and SARS) and in vitro activity against SARS-CoV-2
- Because remdesivir supply is limited, NIH guidelines recommend remdesivir be prioritized for hospitalized patients who require supplemental oxygen but who are not on high-flow oxygen, noninvasive ventilation, mechanical ventilation or extracorporeal membrane oxygenation (ECMO)⁷ (updated 7/25/2020)
- NIH guidelines state a recommendation cannot be made for or against remdesivir in patients on high-flow oxygen, noninvasive ventilation, mechanical ventilation, or ECMO because there is uncertainty regarding benefits of remdesivir in these patients⁷ (added 7/25/2020)
- NIH guidelines state there are insufficient data to recommend for or against use in patients with mild or moderate COVID-19⁷ (updated 6/16/2020)

---


---

NIAD. ACTT-1. NEJM 2020* (added 5/4/20; updated 5/25/20)

Population: 1063 hospitalized patients with advanced disease and lung involvement (88.7% had severe disease)

Design:
- randomized, double-blind, placebo-controlled trial in US, Europe and Asia
- 200 mg on day 1, then 100 mg once/day 2-10 or until discharge or death
- median time from symptom onset to randomization was 9 days

Results:
- recovery time 31% shorter with remdesivir (11 days vs 15 days with placebo; p<0.001)
- lower mortality rate at 14 days (7.1% vs 11.9%; not statistically significant)
- effect appeared to be greatest in hospitalized patients requiring oxygen (baseline ordinal score of 5; this category had largest sample size); mortality difference between remdesivir and placebo groups appeared smaller in patients who did not require oxygen (ordinal score of 4) and in those who required mechanical ventilation (ordinal score of 6)

Limitations:
- preliminary report
J Grein et al. NEJM 2020

Population: 53 hospitalized patients in US, Canada, Europe and Japan with \( \text{SaO}_2 \leq 94\% \) on \( \text{O}_2 \) or room air (n=61)
- 57\% on mechanical compassionate ventilation

Design:
- report on use

Results:
- median follow-up 18 days
- 68\% had improvement in \( \text{O}_2 \) support class; 57\% were extubated; 47\% discharged; 18\% died

JD Goldman et al. NEJM 2020

Population: hospitalized patients w/oxygen saturation \( \leq 94\% \) on ambient air, radiologic evidence of pneumonia

Design:
- randomized, open-label (n = 397)
- remdesivir x 5 days vs 10 days

Results:
- baseline clinical status significantly worse in patients in the 10-day group
- no significant differences between 5 and 10 days of treatment were reported
- 64\% in the 5-day group and 54\% in the 10-day group achieved clinical improvement of \( \geq 2 \) points on a 7-point ordinal scale by day 14
- in a post-hoc analysis, among patients on mechanical ventilation or ECMO at day 5, 40\% in the 5-day group died by day 14 vs 17\% in the 10-day group

Limitations: open-label, no placebo group

FDA warns that coadministration of remdesivir and chloroquine or hydroxychloroquine may decrease the antiviral activity of remdesivir; concurrent use is not recommended\(^\text{12}\) \((\text{added 6/18/2020})\)

FDA Emergency Use Authorization (EUA) expanded on August 28, 2020 to allow use of remdesivir for treatment of COVID-19 in all adult and pediatric hospitalized patients, irrespective of their severity of disease \((\text{initial EUA was for those with severe illness})\)^\text{2} \((\text{updated 8/31/2020})\)

- 31\% shorter recovery time with remdesivir (11 days vs 15 days with placebo) reported in a randomized, double-blind trial \((\text{updated 5/25/2020})\)^\text{3}

- An editorial in NEJM suggests priority be given to a 5-day course of remdesivir for patients at early stages of severe disease\(^\text{10}\)

- The manufacturer has initiated a phase 1a trial of an inhaled, nebulized solution of remdesivir in healthy volunteers; this trial is intended to form the basis for further clinical studies of this formulation in outpatients with COVID-19\(^\text{13}\) \((\text{added 7/9/2020})\)

Gilead filed with the FDA for approval of remdesivir for COVID-19 \((\text{added 8/19/2020})\)

Pregnancy:
- No data are available in pregnant women
Spinner et al. JAMA 2020\textsuperscript{11,16} (updated 8/23/2020)

**Population:** hospitalized patients with moderate COVID-19 (pneumonia, but not reduced oxygen levels) (n = 584)

**Design:** randomized, open-label; remdesivir x 5 days or 10 days in addition to standard care or standard care alone

**Results:**
- median duration of symptoms before day 1 was 8 days in the remdesivir groups and 9 days in the standard care group
- median duration of treatment was 5 days in the 5-day group and 6 days in the 10-day group
- on day 11, the odds of a better clinical status distribution on a 7-point ordinal scale was significantly higher in those treated with remdesivir for 5 days than with standard care (OR 1.65; 95% CI 1.09-2.48; p=0.02); clinical importance unclear
- treatment with remdesivir x 10 days did not reach statistical significance

**Limitations:** open-label; median symptom duration at start of trial was 8 days; only 38% of remdesivir 10-day group received the drug for 10 days

Olender et al. Clin Infect Dis 2020\textsuperscript{15} (added 7/31/2020)

**Population:** hospitalized adults with severe COVID-19 (oxygen saturation ≤94% on room air or requiring supplemental oxygen and pulmonary infiltrates) (n=312 remdesivir; n=818 non-remdesivir)
REMDESIVIR (CONTINUED)

**Design:** comparative analysis of 2 ongoing studies
- a randomized, open-label phase 3 trial comparing 2 courses of remdesivir
- and a retrospective cohort study in patients receiving standard-of-care

**Results:**
- 74.4% of remdesivir-treated patients recovered at day 14 vs 59.0% of non-remdesivir-treated patients (adjusted OR 2.03; p<0.001)
- 7.6% of remdesivir-treated patients died vs 12.5% in non-remdesivir-treated patients (adjusted OR 0.38; p=0.001)

**Limitations:** comparative analysis of interim data sponsored by manufacturer

**Inhaled Remdesivir (added 7/9/2020)**
- The manufacturer has initiated a phase 1a trial evaluating remdesivir in an inhaled, nebulized formulation in healthy volunteers

**NIH Adaptive COVID-19 Treatment Trial 3 (ACTT 3) (added 8/9/2020)**
- A randomized, double-blind trial comparing remdesivir plus interferon beta 1a to remdesivir alone has begun
- Expected to enroll >1000 adults

**NIH Adaptive COVID-19 Treatment Trial 2 (ACTT-2) 202017 (added 9/18/2020)**

**Population:** hospitalized patients with COVID-19 (n>1000)

**Design:** Phase 3 randomized, double-blind, placebo-controlled trial
**remdesivir plus baricitinib 4 mg vs remdesivir alone**

**Results:**
- mean recovery time was about 1 day shorter with the combination of remdesivir plus baricitinib compared to remdesivir alone, a statistically significant difference
- the combination improved outcomes at day 15 on an ordinal scale compared to remdesivir alone

**Limitations:** limited data available; not yet published or peer reviewed

---

## Convalescent Plasma

### CONVALESCENT PLASMA

*(updated 8/23/2020)*

### Dosage:
- Optimal dosage not established
- One or two 200-ml infusions

### Case series
- **Case series** of 5 critically ill patients with COVID-19 and ARDS in China; administration of convalescent plasma improved clinical status (e.g., body temperature normalized, viral load decreased, antibody titers increased, ARDS resolved, weaning from mechanical ventilation).
- **Case series** of 10 patients with severe COVID-19; clinical symptoms improved within 3 days and improvement in lung lesions reported within 7 days

**Li et al. JAMA 2020** *(added 8/16/2020)*

**Population:** hospitalized patients in China with severe or life-threatening COVID-19 (n=103)

**Design:** open-label, multicenter, randomized trial

- Convalescent plasma plus standard treatment vs standard treatment alone
- Plasma units with an S-RBD–specific IgG titer of at least 1:640 were used
- Median time from symptom onset to randomization: 30 days

**Results:**
- Trial stopped early
- Clinical improvement within 28 days occurred in 51.9% of patients treated with convalescent plasma vs 43.1% of those given standard treatment alone, not a statistically significant difference (p=0.26)
- In those with severe disease, clinical improvement occurred in 91.3%

### Adverse Effects:
- No severe adverse effects were reported in case series
- Risks expected to be similar to those of other transfusions
- Transfusion-transmissible infection risk is very low in the US
- Allergic transfusion reactions, transfusion associated circulatory overload (TACO), and transfusion related acute injury (TRALI)
- Theoretical risk of antibody-dependent enhancement (ADE) presumably due to antibodies from previous infection with other coronaviruses
- May lower natural immune response when given for prophylaxis
- Passive antibody therapy by infusion of convalescent plasma may prevent infection or reduce severity of illness
- Used previously for treatment of SARS-CoV-1, MERS, Ebola, and H1N1 influenza
- Most likely to be effective when given as prophylaxis or early in the course of disease
- Clinical trials underway in the US
- NIH guidelines state there are insufficient clinical data to recommend either for or against use of convalescent plasma
- Surviving Sepsis Campaign guidelines suggest against routine use of convalescent plasma in critically ill adults
- FDA issued an Emergency Use Authorization for convalescent plasma *(added 8/19/2020)*
- NIH released statement following FDA EUA (Sept 1, 2020) stating insufficient data to recommend for or against use of convalescent plasma for COVID-19,
- Serious adverse effects infrequent, but long-term risks, including whether use of convalescent plasma attenuates the immune response to SARS-CoV-2 making patients more susceptible to reinfection, are unknown
with convalescent plasma vs 68.2% with standard care alone (p=0.03)
and in those with life-threatening disease in 20.7% vs 24.1% (p=0.83)
- 28-day mortality was 15.7% with convalescent plasma vs 24.0% with standard care (p=0.30)
- Negative conversion rate of viral PCR at 72 hours was 87.2% with convalescent plasma vs 37.5% with standard care (p<0.001)

Limitations: trial stopped early before full enrollment reached

MJ Joyner et al MedRxiv 2020
(added 8/17/2020)
Population: hospitalized patients in the US with severe or life-threatening acute COVID-19 respiratory syndrome (n=35,322)
Design: open-label exploratory analysis of patients who received convalescent plasma through an Expanded Access Program in the US
Results:
- 52.3% of patients in ICU; 27.5% on mechanical ventilation
- 7-day mortality rate 8.7% in patients transfused ≤ 3 days of diagnosis and 11.9% in patients transfused ≥ 4 days after diagnosis (p<0.001); 30-day mortality was 21.6% vs 26.7% (p<0.0001)
- 7-day mortality was 8.9% with high IgG plasma, 11.6% with medium IgG plasma, and 13.7% with low IgG plasma
Limitations: observational, not peer reviewed; authors state efficacy signals are preliminary
ARDS = acute respiratory distress syndrome

# Intravenous Immune Globulin (IVIG)

**INTRAVENTOUS IMMUNE GLOBULIN (IVIG)**  
*(added 6/8/2020)*

## Dosage:
- Optimal dosage for COVID-19 unclear
- Phase 3 trial of *Octagam* will use a dosage of 0.5 g/kg IV infusion over 2 hours x 4 days

## W Cao et al. Open Forum Infect Dis 2020<sup>1</sup>
**Population:** Hospitalized patients in China with severe disease and deteriorating course *(n = 3)*  
**Design:** Case series; patients received IVIg at the start of respiratory distress  
**Results:** all 3 patients had clinical improvement; no fever within 1-2 days, alleviation of breathing difficulties in 3-5 days  
**Limitations:** small case series, 2 patients also received antivirals, 1 received steroids

## Xie et al. J Infect 2020<sup>2</sup>
**Population:** ICU patients with severe or critical illness in Wuhan, China *(n=58)*  
**Design:** retrospective review of 58 cases  
**Results:** administration of IVIg within 48 hrs of hospital admission was associated with reduced 28-day mortality, shorter hospital stay, and reduced ventilator use compared to administration after 48 hours  
**Limitation:** small retrospective study

## Shao et al. 2020<sup>3</sup>
**Population:** Hospitalized severely and critically ill patients *(n=325)*  
**Design:** multicenter retrospective cohort study  
**Results:**  
- IVIG not associated with improved 28- or 60-day mortality compared to no IVIG in overall cohort

## Adverse Effects:
- Rarely can cause anaphylaxis, aseptic meningitis, renal failure, thromboembolism, hemolytic reactions, transfusion-related lung injury
- Used for treatment of immune disorders and as an adjunct for treatment of severe pneumonia in influenza patients; modulates immune inflammation, improves passive immunity
- Existing IVIG product unlikely to contain antibodies against SARS-CoV-2
- FDA approved an investigational new drug application (IND) for a phase 3 trial with *Octagam* 10% in COVID-19 patients with severe disease progression *(SpO2≤93%, requiring oxygen supplementation)*<sup>4</sup>
- Surviving Sepsis Campaign guidelines suggest against routine use of standard IVIG in critically ill adults<sup>5</sup>
- NIH guidelines recommend against use of non-SARS-CoV-2-specific IVIG outside of the context of a clinical trial for treatment of COVID-19; they state this should not preclude use of IVIG when otherwise indicated for treatment of complications arising during the course of COVID-19 illness<sup>6</sup>
- NIH guidelines state there are insufficient data to recommend for or against use of SARS-CoV-2 immunoglobulins<sup>6</sup> *(added 7/22/2020)*
- Shortages have been an issue (even prior to COVID-19)
INTRAVENOUS IMMUNE GLOBULIN (IVIG) (CONTINUED)

- Duration of hospitalization and disease were longer in patients treated with IVIG than in those who were not
- In a subgroup analysis, IVIG was associated with reduced 28-day mortality in critically ill patients

Limitation: not peer reviewed, IVIG group more likely to have coronary heart disease and severe COVID-19

## Monoclonal Antibodies

<table>
<thead>
<tr>
<th>LY-CoV555</th>
<th><strong>NIH ACTIV-2</strong></th>
<th></th>
<th><strong>NIH ACTIV-3</strong></th>
<th></th>
<th><strong>BLAZE-1 2020</strong> <em>(added 9/17/2020)</em></th>
</tr>
</thead>
<tbody>
<tr>
<td>(Eli Lilly/AbCellera) <em>(updated 9/17/2020)</em></td>
<td>Phase 2 trial</td>
<td>Expected to enroll 200 outpatients with mild to moderate COVID-19 symptoms for &lt; 10 days</td>
<td>Phase 3 study; LY-CoV555 vs placebo</td>
<td>Phase 3 trial of LY-CoV555 antibody for prophylaxis of COVID-19 in nursing home residents ongoing</td>
<td>Population: outpatients with mild to moderate COVID-19</td>
</tr>
<tr>
<td></td>
<td>LY-CoV555 vs placebo</td>
<td></td>
<td>Expected to enroll 300 hospitalized patients with mild to moderate COVID-19 with &lt; 13 days of symptoms</td>
<td></td>
<td>Design: phase 2 randomized, double-blind, placebo-controlled</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Phase 3 trial of LY-CoV555 antibody for prophylaxis of COVID-19 in nursing home residents ongoing</td>
<td></td>
<td>LY-CoV555 700 mg, 2800 mg, or 7000 mg vs placebo</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Results:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Change from baseline in viral load at day 11 was statistically significant compared to placebo with the 2800 mg dose only</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Complete viral clearance by day 11 was achieved by most patients, including those in the placebo group</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>In additional analysis, LY-CoV555 improved viral clearance at day 3</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Hospitalization or ER visit in 1.7% on LY-CoV555 vs 6% on placebo</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Limitations: interim data; not peer reviewed; unclear if earlier evaluation</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>LY-CoV555 is an investigational monoclonal antibody for treatment of COVID-19</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>The antibody was discovered in a blood sample from a recovered COVID-19 patient</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Administered IV</td>
</tr>
</tbody>
</table>
of viral clearance would have shown a difference at lower dosages

<table>
<thead>
<tr>
<th>REGN-COV-2</th>
<th>Clinical trials ongoing</th>
<th>Investigational combination of 2 SARS-CoV-2 neutralizing antibodies that bind to the spike protein</th>
<th>Partnered with Roche</th>
</tr>
</thead>
<tbody>
<tr>
<td>(Regeneron)</td>
<td>Two phase 2/3 trials in hospitalized and non-hospitalized patients</td>
<td>Phase 3 RECOVERY trial</td>
<td>Phase 3 prevention trial with NIAID and NIH</td>
</tr>
<tr>
<td>(added 9/17/2020)</td>
<td>Phase 3 RECOVERY trial</td>
<td>Investigational combination of 2 SARS-CoV-2 neutralizing antibodies (AZD8895 and AZD1061) that bind to distinct parts of the SARS-CoV-2 spike protein</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Phase 3 prevention trial with NIAID and NIH</td>
<td>Discovered at Vanderbilt University Medical Center</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>AstraZeneca proprietary technology being used to extend the half-life</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Being administered IV and IM in phase 1 trial</td>
<td></td>
</tr>
</tbody>
</table>

| AZD7442 | Clinical trials ongoing | Investigational combination of 2 SARS-CoV-2 neutralizing antibodies (AZD8895 and AZD1061) that bind to distinct parts of the SARS-CoV-2 spike protein |
|---------|-------------------------|-------------------------------------------------------------------------------------------------|---------------------|
| (AstraZeneca) | Phase 1 dose-escalation trial ongoing in the UK | Discovered at Vanderbilt University Medical Center |
| (added 9/17/2020) | | AstraZeneca proprietary technology being used to extend the half-life |
| | | Being administered IV and IM in phase 1 trial |

## Glutathione and N-acetylcysteine

| **GLUTATHIONE** | Adverse Effects:  
- Nausea, vomiting, other gastrointestinal symptoms, and rash, with or without fever  
- Anaphylactoid reactions to IV acetylcysteine, including rash, pruritus, angioedema, bronchospasm, tachycardia, and hypotension have occurred.  
- Intracellular anti-oxidant with possible antiviral properties  
- One researcher has hypothesized that glutathione deficiency is risk factor for severe COVID-19 illness  
- NAC has been proposed for treatment of multiple respiratory conditions and viral illnesses |
|---|---|
| **Dosage:** 2 g IV/PO used in case report\(^1\) | **Pregnancy:**  
- Acetylcysteine crosses the placenta |
| **N-ACETYLCYSTEINE (NAC; GLUTATHIONE PRECURSOR)**  
6 g/day IV\(^2\)  
*(Added 4/28/2020)* | **Population:** Two patients with COVID-19 pneumonia  
**Regimen:** 2 g IV/PO glutathione  
**R Horowitz et al. Resp Med Case Rep 2020\(^1\)**Case Report |

---

<table>
<thead>
<tr>
<th>Stem Cell Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MESENCHYMAL STEM CELL THERAPY</strong> <em>(updated 7/21/2020)</em></td>
</tr>
</tbody>
</table>

**Remestemcel-L (Ryoncil)**
- 10 patients with ARDS treated with remestemcel-L under the FDA compassionate use program with encouraging results
- Randomized clinical trial to be conducted at Mount Sinai in NY
- **Results:** Dyspnea improved within 1 hour of administration

**Leng et al. Aging Dis 2020¹ (updated 7/21/2020)**
**Population:** hospitalized patients with COVID-19 pneumonia in China *(n=10)*
**Design:** pilot trial; 7 patients (1 critical, 4 severe, 2 common-type illness) treated with mesenchymal stem cells and 3 (severe illness) treated with placebo
**Results:**
- Pulmonary function and symptoms improved within 2 days of transplantation
- All patients in the treatment group recovered
**Limitation:** small pilot study

**Adverse Effects:**
- Risks in patients with COVID-19 not established
- Possible product contamination, infusion site reactions, thrombosis, infection, tumor growth
- Remestemcel-L well tolerated in trials reported by the manufacturer in children with GVHD

**Pregnancy:**
- There are inadequate data on the use of stem cell therapies in pregnant women
- May mitigate the effects of cytokines released in response to the virus and limit lung damage in patients with severe disease by decreasing production of proinflammatory cytokines, increased production of anti-inflammatory cytokines, and recruitment of anti-inflammatory cells

**FDA**
- FDA approved an expanded access protocol for compassionate use of remestemcel-L in children with multisystem inflammatory syndrome associated with COVID-19¹ (updated 7/21/2020)
- NIH guidelines recommend against use of mesenchymal stem cells, except in a clinical trial³ (updated 7/21/2020)
- FDA has warned about safety concerns with use of unapproved or illegal stem cell therapies⁵ (updated 7/21/2020)

---

<table>
<thead>
<tr>
<th>OLEANDRIN</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>(added 8/19/2020)</strong></td>
</tr>
<tr>
<td>▪ No published <em>in vivo</em> data on use of oleandrin for treatment or prevention of COVID-19</td>
</tr>
<tr>
<td>▪ An <em>in vitro</em> study (not peer reviewed) suggested that oleandrin may inhibit SARS-CoV-2 replication</td>
</tr>
</tbody>
</table>

**Adverse Effects:**

▪ Toxicity includes nausea, vomiting, abdominal pain, diarrhea (possibly bloody stools), anorexia, arrhythmias, drowsiness, tremors, seizures, coma, death

▪ Toxicity occurs several hours after ingestion

▪ There are no available data to support use of oleandrin for COVID-19 and it can have serious, life-threatening toxicity; avoid use

▪ Toxic cardiac glycoside from the *Nerium oleander* plant

▪ All parts of the oleander plant are toxic; it is responsible for cases of accidental poisoning worldwide

---

### RECOVERY Trial 2020

**Population:** Hospitalized patients in the UK (n=6425)

**Design:**
- Randomized, controlled, open-label, adaptive, platform trial designed to evaluate a range of treatments for COVID-19 including dexamethasone
- Dexamethasone 6 mg PO or IV once daily (n=2104) x 10 days vs usual care (n=4321)

**Results:** 28-day mortality rates (dexamethasone vs usual care)
- **Overall:** 22.9% vs 25.7% (p<0.001)
- Patients on invasive mechanical ventilation: 29.3% vs 41.4% (rate ratio 0.64; 95% CI 0.51-0.81)
- Oxygen without invasive mechanical ventilation: 23.3% vs 26.2% (rate ratio 0.82; 95% CI 0.72-0.94)
- No respiratory support at randomization: 17.8% vs 14.0% (rate ratio 1.19; 95% CI 0.91-1.55)

**Limitation:** Preliminary results; open-label study

### Comments
- Anti-inflammatory effects may modulate immune-mediated lung damage
- Authors of RECOVERY trial state that treating 8 ventilated patients or 25 patients requiring oxygen would prevent 1 death
- NIH guidelines recommend use of dexamethasone 6 mg daily for up to 10 days in mechanically ventilated patients and those who are not mechanically ventilated but require supplemental oxygen
- IDSA guidelines recommend use of dexamethasone (or methylprednisolone or prednisone if dexamethasone is not available) for hospitalized patients with severe illness (patients with SpO$_2$≤94% on room air, and those who require supplemental oxygen, mechanical ventilation, or ECMO)
- NIH and IDSA recommend against use of dexamethasone for treatment of COVID-19 in patients who do not require supplemental oxygen
- NIH guidelines state it is unknown whether other corticosteroids, such as prednisone, methylprednisolone, or hydrocortisone have benefits similar to those of dexamethasone in patients with COVID-19 (added 7/20/2020)
CORTICOSTEROIDS (DEXAMETHASONE, HYDROCORTISONE) (continued)


**Population:** hospitalized patients in NYC (n=1806)

**Design:** observational study
- patients treated with steroids within 48 hrs of admission (n=148) compared to those who did not receive steroid treatment

**Results:**
- patients in the steroid group were more likely to have COPD, asthma, rheumatoid arthritis, or lupus, or to have taken steroids in the year before admission than those in the control group
- overall, early use of glucocorticoids was not associated with mortality or mechanical ventilation
- in patients with CRP ≥ 20 mg/dL, glucocorticoid treatment was associated with a significant reduction in risk of mortality or mechanical ventilation
- in those with CRP < 10 mg/dL, glucocorticoid use was associated with a significant increase in the risk of mortality or mechanical ventilation

**Limitations:** observational data

**Tomazini et al. JAMA 2020⁶ (added September 3, 2020)**

**The CoDEX Trial**

**Population:** ICU patients w/ mod-severe ARDS (n=299)

**Design:**
- randomized, open-label trial

**WHO recommends systemic corticosteroids (dexamethasone 6 mg PO or IV daily or hydrocortisone 50 mg IV q8h x 7-10 days) to treat patients with severe and critical COVID-19**¹⁰ (added September 3, 2020)

**WHO recommends against use of systemic corticosteroids in patients with non-severe disease**¹⁰ (added September 3, 2020)

**Pregnancy:**
- NIH recommends use of dexamethasone in pregnant women with COVID-19 who are mechanically ventilated or who require supplemental oxygen but are not mechanically ventilated³ (added 7/20/2020)
- Monitor for hypoadrenalism in newborns of mothers who received substantial doses
**CORTICOSTEROIDS**  
(DEXAMETHASONE, HYDROCORTISONE)  
(continued)

<table>
<thead>
<tr>
<th>EFFICACY</th>
<th>ADVERSE EFFECTS/INTERACTIONS</th>
<th>COMMENTS</th>
</tr>
</thead>
</table>
| ▪ dexamethasone 20 mg IV daily x 5 days, then 10 mg daily x 5 days or until hospital discharge plus standard care vs standard care  
**Results:**  
▪ patients in dexamethasone group had significantly more ventilator-free days (days alive and free of mechanical ventilation) compared to control group (6.6 vs 4.0)  
▪ no significant difference in all-cause mortality at 28 days, ICU-free days during first 28 days, mechanical ventilation duration at 28 days  
**Limitations:**  
▪ open-label  
▪ 35% of patients in control group received steroids  
▪ trial was underpowered to detect significant differences in secondary endpoints |  
| **PF Dequin et al. JAMA 2020**  
*(added September 3, 2020)*  
**Population:** ICU patients w/ respiratory failure  
**Design:**  
▪ randomized double-blind trial (n=149)  
▪ low-dose hydrocortisone vs placebo  
**Results:**  
▪ trial ended early  
▪ no significant difference in rate of treatment failure (death or respiratory support) at day 21 (42.1% w/ low-dose |  

---

- 23 -
<table>
<thead>
<tr>
<th>DRUG AND DOSAGE</th>
<th>EFFICACY</th>
<th>ADVERSE EFFECTS/INTERACTIONS</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>CORTICOSTEROIDS (DEXAMETHASONE, HYDROCORTISONE) (continued)</td>
<td>hydrocortisone vs 50.7% w/placebo</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Limitations:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>▪ trial stopped early so</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>▪ underpowered to detect</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>▪ significant differences</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>REMAP-CAP JAMA 2020*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>(added September 3, 2020)</em></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Population:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>▪ ICU patients w/ respiratory or CV support (n=384)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Design:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>▪ open-label adaptive platform trial</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>▪ IV hydrocortisone 50 or 100 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>q6h x 7 days vs hydrocortisone 50</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>mg q6h when shock was clinically</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>evident vs no hydrocortisone</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Results:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>▪ No difference in median organ-</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>support free days in patients</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>treated with fixed-dose or shock-</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>dependent hydrocortisone</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>compared to no hydrocortisone</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(all 0 days)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>▪ Bayesain model found both</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>hydrocortisone regimens probably</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>superior to no hydrocortisone</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Limitations:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>▪ trial stopped early so</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>▪ underpowered to detect</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>▪ significant differences</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DRUG AND DOSAGE</td>
<td>EFFICACY</td>
<td>ADVERSE EFFECTS/INTERACTIONS</td>
<td>COMMENTS</td>
</tr>
<tr>
<td>----------------</td>
<td>----------</td>
<td>-----------------------------</td>
<td>----------</td>
</tr>
</tbody>
</table>
| CORTICOSTEROIDS (DEXAMETHASONE, HYDROCORTISONE) (continued) | **WHO JAMA 2020**<sup>9</sup> *(added September 3, 2020)*  
**Population:** critically ill patients *(n=1703)*  
**Design:**  
▪ meta-analysis  
▪ dexamethasone, hydrocortisone or methylprednisolone vs placebo or usual care  
**Results:**  
▪ 28-day all-cause mortality was lower in those treated with a corticosteroid (OR 0.64 for dexamethasone; 0.69 for hydrocortisone; 0.91 for methylprednisolone) | | |

<table>
<thead>
<tr>
<th>INHALED CORTICOSTEROIDS (ICSs)</th>
<th>EFFICACY</th>
<th>ADVERSE EFFECTS/INTERACTIONS</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Inhaled Corticosteroids</strong></td>
<td></td>
<td></td>
<td><strong>Hypothesized that inhaled corticosteroids delivered to the lungs may inhibit adhesion and inflammatory effects of cytokines released in response to the virus</strong></td>
</tr>
<tr>
<td><strong>Ciclesonide (Alvesco)</strong></td>
<td></td>
<td></td>
<td><strong>Ciclesonide may have anti-viral activity against SARS-CoV-2</strong></td>
</tr>
<tr>
<td><strong>Budesonide (Pulmicort Flexhaler)</strong></td>
<td></td>
<td></td>
<td><strong>NIH guidelines recommend that patients with COVID-19 who are using inhaled corticosteroids for treatment of asthma or COPD should not discontinue treatment</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td><strong>No data available on use of inhaled corticosteroids for treatment of COVID-19 from randomized controlled trials</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td><strong>Pregnancy:</strong> <strong>Low-to-moderate doses appear to be safe for use during pregnancy</strong></td>
</tr>
</tbody>
</table>

**Adverse Effects:**
- Local adverse effects include oral candidiasis (thrush), dysphonia, and reflex cough and bronchospasm
- High doses may cause HPA axis suppression, changes in bone density, and development of cataracts or glaucoma
- Increases the risk of pneumonia in patients with COPD
- Rinse mouth after use to reduce the risk of local adverse effects

**Drug Interactions:**
- Significant drug interactions less likely with inhaled corticosteroids than with systemic formulations
- Strong CYP3A4 inhibitors may increase serum concentrations of inhaled corticosteroids

## IL-6 Inhibitors

### Dosage:
- No clinical trial data yet
- Optimal dosage not established
- High and low IV doses are expected to be studied

### Efficacy
- Phase 3 trials will continue to enroll critical patients only
  - U.S. phase 3 trial in mechanically ventilated patients has been stopped because the trial did not meet primary or key secondary endpoints and negative trends were found in a subgroup of critically ill patients who were not mechanically ventilated at baseline

### Adverse Effects/Interactions
- **Adverse Effects:**
  - Neutropenia, thrombocytopenia, serious infections, hypersensitivity reactions including anaphylaxis
- **Drug Interactions:**
  - May normalize CYP enzyme formation; could increase metabolism and decrease serum concentrations of drugs with narrow therapeutic indices that are metabolized by CYP isozymes
  - Hematologic toxicity may be additive with other drugs such as linezolid, clozapine, or azathioprine

### Comments
- Monoclonal antibody that inhibits IL-6 receptors; may mitigate the effects of cytokines released in response to the virus and limit lung damage in patients with severe disease
- NIH guidelines recommend against use of IL-6 inhibitors, except in a clinical trial (updated 8/29/2020)
- Crosses the placenta, especially in the third trimester, and may affect the immune response in an exposed infant
- Parturition is associated with IL-6 increases in the cervix and myometrium; inhibition of IL-6 may lead to possible delays of parturition
- Not associated with embryotoxic or teratogenic effects when given in high doses to pregnant monkeys
<table>
<thead>
<tr>
<th>DRUG AND DOSAGE</th>
<th>EFFICACY</th>
<th>ADVERSE EFFECTS/INTERACTIONS</th>
<th>COMMENTS</th>
</tr>
</thead>
</table>
**Population:** hospitalized patients in China (n=191)  
**Design:** retrospective study  
**Results:** elevated levels of IL-6 were associated with severe illness and death  
Xu et al 2020<sup>7</sup>  
**Population:** hospitalized patients with severe or critical illness and elevated IL-6 levels; (n=20)  
**Design:** case series; tocilizumab added to standard care  
**Results:** improvement in fever (all patients), oxygen requirement (75% of patients), reduction in CRP levels (in 82.4% of patients), lung opacities on CT scan improved (90.5% of patients)  
**Limitations:** not peer-reviewed  
**CORIMUNO-19 (added 5/4/2020)**  
**Population:** hospitalized patients in France with moderate to severe illness not requiring ICU care upon admission (n=129)  
**Design:** open-label<sup>1</sup>; tocilizumab added to standard care vs standard care alone  
**Results:** significantly fewer patients who received tocilizumab died or required ventilation at day 14  
**Limitations:** open-label; not yet published | **Adverse Effects:**  
▪ Neutropenia, thrombocytopenia, serious infections, hypersensitivity reactions including anaphylaxis  
**Drug Interactions:**  
▪ May normalize CYP enzyme formation; could increase metabolism and decrease serum concentrations of drugs with narrow therapeutic indices that are metabolized by CYP isozymes  
▪ Hematologic toxicity may be additive with other drugs such as linezolid, clozapine, or azathioprine | **Monoclonal antibody that inhibits IL-6 receptors; may mitigate the effects of cytokines released in response to the virus and limit lung damage in patients with severe disease**  
**Surviving Sepsis Campaign guidelines state that there is insufficient evidence to make a recommendation on use of tocilizumab**<sup>8</sup>  
**Infectious Diseases Society of America recommends use only in the context of a clinical trial**<sup>9</sup>  
**NIH guidelines recommend against use of an IL-6 inhibitor, except in a clinical trial** (updated 8/29/2020)  
**Randomized, controlled trials are ongoing in the US**  
**Pregnancy:**  
▪ Crosses the placenta, especially in the third trimester, and may affect the immune response in an exposed infant  
**Parturition is associated with IL-6 increases in the cervix and myometrium; inhibition of IL-6 may lead to possible delays of parturition**  
**Increased incidence of abortion/embryo-fetal death when given to pregnant monkeys during the period of organogenesis** |

Dosage:  
▪ Optimal dosage not established  
▪ 8 mg/kg (max 400 mg) IV once<sup>5</sup>  
▪ Infuse over 1 hour  
▪ Optimal timing of administration is unclear
<table>
<thead>
<tr>
<th>DRUG AND DOSAGE</th>
<th>EFFICACY</th>
<th>ADVERSE EFFECTS/INTERACTIONS</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>TOCILIZUMAB (CONTINUED)</strong></td>
<td><strong>Somers et al. 2020</strong>[^10] (added 6/18/2020; updated 7/14/2020)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Population:</strong> hospitalized patients requiring mechanical ventilation (n=154)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>▪ tocilizumab-treated patients were younger (55 yrs vs 60 yrs), less likely to have chronic pulmonary disease (10% vs 28%), and had lower D-dimer values at intubation (median 2.4 vs 6.5 mg/dL)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Design:</strong> single-center cohort; patients treated with tocilizumab vs patients not treated with tocilizumab</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Results:</strong> median follow-up 47 days</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>▪ tocilizumab associated with a reduced risk of death (hazard ratio 0.55; 95% CI 0.33,0.90)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>▪ tocilizumab associated with an increased risk of superinfections (54% vs 26%; p&lt;0.001)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>▪ no significant difference in 28-day case fatality rate in patients treated with tocilizumab who had superinfections vs those who did not (22% vs15%; p=0.42)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Limitation:</strong> observational data</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**COVACTA 2020**[^12] (added 8/16/2020) |  |  |  |
<p>| <strong>Population:</strong> hospitalized patients with severe COVID-19 pneumonia (n=450) |  |  |  |
| <strong>Design:</strong> randomized, double-blind, placebo-controlled |  |  |  |
| ▪ IV tocilizumab plus standard of care vs placebo plus standard of care |  |  |  |</p>
<table>
<thead>
<tr>
<th>DRUG AND DOSAGE</th>
<th>EFFICACY</th>
<th>ADVERSE EFFECTS/INTERACTIONS</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>TOCILIZUMAB (CONTINUED)</td>
<td>Results: ▪ No significant difference between tocilizumab and placebo in the primary endpoint of clinical status on a 7-point scale at week 4 ▪ No difference between groups in percentage of patients who died by week 4 (19.7% tocilizumab vs 19.4% placebo)</td>
<td>Limitations: not yet published</td>
<td></td>
</tr>
<tr>
<td>EMPACTA 2020[^1](added 9/18/2020)</td>
<td>Population: hospitalized patients with COVID-19 pneumonia (SpO2 &lt;94% on ambient air with no mechanical ventilation) (n=389) ▪ 85% of patients were from racial and ethnic minority groups</td>
<td>Design: Phase 3 randomized, double-blind, placebo-controlled trial ▪ Tocilizumab plus standard care vs placebo plus standard care</td>
<td>Results: ▪ Mechanical ventilation or death was less likely in patients treated with tocilizumab compared to those who were not (p=0.0348; HR 0.56)</td>
</tr>
</tbody>
</table>
1. FDA-approved for treatment of rheumatoid arthritis.
4. FDA-approved for chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome, rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis.
5. Experimental dosage used for treatment of COVID-19 in trials; optimal dosage not established.
### ANAKINRA – KINERET (BIOVITRUM AB)  
**(updated 7/27/2020)**

**Dosage:**
- Optimal dosage for COVID-19 unknown\(^1,2,3\)
- In a trial being conducted by the manufacturer, anakinra is being administered IV at a dosage of 100 mg q6h x 15 days. According to US Kineret labeling, the drug is indicated for SC administration.

**Population:**
- Consecutive hospitalized patients with moderate-to-severe ARDS and serum C-reactive protein $\geq$100 mg/L, ferritin $\geq$900 ng/mL, or both; not on mechanical ventilation
**Design:** retrospective cohort study; single hospital in Italy
- Addition of anakinra vs standard treatment (HCQ + LPV/RTV)

**Results:**
- Improved survival with high-dose (5 mg/kg IV bid) anakinra vs standard treatment (90% vs 56%; p=0.009)
- Mechanical ventilation-free survival similar between groups (72% vs 50%; p=0.15)
- Associated with reduced serum C-reactive protein and improved respiratory function

**Limitations:** small, retrospective study

### Cavalli et al. Lancet Rheum 2020\(^4\)
- In a trial being conducted by the manufacturer, anakinra is being administered IV at a dosage of 100 mg q6h x 15 days. According to US Kineret labeling, the drug is indicated for SC administration.

### Adverse Effects/

### Cavalli et al. Lancet Rheum 2020\(^4\)

**Population:** consecutive hospitalized patients with moderate-to-severe ARDS and serum C-reactive protein $\geq$100 mg/L, ferritin $\geq$900 ng/mL, or both; not on mechanical ventilation

**Design:** retrospective cohort study; single hospital in Italy

**Results:** at 21 days
- Improved survival with high-dose (5 mg/kg IV bid) anakinra vs standard treatment (90% vs 56%; p=0.009)
- Mechanical ventilation-free survival similar between groups (72% vs 50%; p=0.15)
- Associated with reduced serum C-reactive protein and improved respiratory function

**Limitations:** small, retrospective study

### Cauchois et al. Proc Natl Acad Sci U S A 2020\(^5\) (added 7/27/2020)

**Population:** hospitalized patients in France with hypoxic pneumonia or ARDS (n=22)

**Design:** retrospective
- anakinra plus standard care compared to standard care alone
- anakinra dosage: 300 mg IV x 5 days, then tapered to 200 mg/d x 2 days, then 100 mg x 1 day

**Adverse Effects:**
- Injection-site reactions, infections, neutropenia, thrombocytopenia, hepatic transaminase elevations

**Drug Interactions:**
- Use with TNF inhibitors or other biologics may increase risk of serious infections and neutropenia and should be avoided

**Comments:**
- Clinical trials are ongoing\(^1,2\)
- IL-1 receptor antagonist; IL-1 mediates inflammatory and immune responses antagonist
- May mitigate the effects of cytokines released in response to the virus and limit lung damage in patients with severe disease
- NIH guidelines state there are insufficient clinical data to recommend either for or against use of IL-1 inhibitors\(^3\) *(updated 4/28/2020)*
- FDA-approved for treatment of rheumatoid arthritis and neonatal-onset multisystem inflammatory disease.

**Pregnancy:**
- Not associated with adverse pregnancy outcomes in small retrospective studies in humans or in animal studies
<table>
<thead>
<tr>
<th>DRUG AND DOSAGE</th>
<th>Efficacy</th>
<th>ADVERSE EFFECTS/INTERACTIONS</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>ANAKINRA (continued)</td>
<td><strong>Results:</strong> ▪ compared to standard care alone, all anakinra-treated patients had clinical improvement (p&lt;0.01), decreases in oxygen requirements (p&lt;0.05), and more days off invasive mechanical ventilation (p&lt;0.06) ▪ there were no deaths in the anakinra group and 1 death in the standard care group ▪ significant reduction of fever and CRP by day 3 with anakinra <strong>Limitations:</strong> small retrospective study</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>DRUG AND DOSAGE</th>
<th>EFFICACY</th>
<th>ADVERSE EFFECTS/INTERACTIONS</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>JANUS KINASE (JAK) Inhibitors</td>
<td><strong>BARICITINIB – OLUMIANT (LILLY)</strong> (updated 9/18/2020)</td>
<td>NIH Adaptive COVID-19 Treatment Trial 2 (ACTT-2) 2020^6 (added 9/18/2020)</td>
<td>FDA-approved for treatment of rheumatoid arthritis</td>
</tr>
<tr>
<td><strong>Dosage:</strong></td>
<td><strong>Population:</strong> hospitalized patients with COVID-19 (n&gt;1000)</td>
<td>Adverse Effects:</td>
<td>Inhibits JAK enzymes, which mediate signaling of proinflammatory cytokines including IL-6; may mitigate the effects of cytokines released in response to the virus and limit lung damage in patients with severe disease</td>
</tr>
<tr>
<td>- Optimal dosage for COVID-19 not established</td>
<td><strong>Design:</strong> Phase 3 randomized, double-blind, placebo-controlled trial</td>
<td>▪ Nausea is common</td>
<td>NIH recommends against use of JAK inhibitors, except in the context of a clinical trial, because of their broad immunosuppressive effect^1 (updated 4/28/2020)</td>
</tr>
<tr>
<td>- 2 mg PO daily</td>
<td>▪ remdesivir plus baricitinib 4 mg vs remdesivir alone</td>
<td>▪ Serious, sometimes fatal, infections, including multi-dermatomal herpes zoster and tuberculosis (TB)</td>
<td>Should not be used in patients with severe hepatic impairment (Child-Pugh C) or moderate or severe renal impairment (eGFR &lt;60 mL/min/1.73 m2)</td>
</tr>
<tr>
<td></td>
<td><strong>Results:</strong></td>
<td>▪ Serious, sometimes fatal, thromboembolic events</td>
<td>Treatment should be withheld if the absolute lymphocyte count falls below 500 cells/mm^3, the absolute neutrophil count falls below 1000 cells/mm^3, or the hemoglobin level falls below 8 g/dL</td>
</tr>
<tr>
<td></td>
<td>▪ mean recovery time was about 1 day shorter with the combination of remdesivir plus baricitinib compared to remdesivir alone, a statistically significant difference</td>
<td>▪ Malignancy, GI perforation, neutropenia, lymphopenia, anemia, thrombocytosis, and elevations in liver enzymes, creatine phosphokinase levels, and lipid levels have also been reported</td>
<td>Pregnancy:</td>
</tr>
<tr>
<td></td>
<td>▪ the combination improved outcomes at day 15 on an ordinal scale compared to remdesivir alone</td>
<td>▪ Drug Interactions:</td>
<td>▪ Administration to pregnant animals resulted in reduced fetal weights, embryolethality, and skeletal malformations</td>
</tr>
<tr>
<td></td>
<td><strong>Limitations:</strong> limited data available; not yet published or peer reviewed</td>
<td>▪ The strong organic anion transporter 3 (OAT3) inhibitor probenecid doubled baricitinib exposure; concurrent use of with strong OAT3 inhibitors is not recommended</td>
<td></td>
</tr>
</tbody>
</table>

- 34 -
**DRUG AND DOSAGE**

**RUXOLITINIB – JAKAFI (INCYTE/NOVARTIS)**

**Dosage:**
- Optimal dosage not established
- 10 mg PO bid x 14 days
- Taper dosage when stopping: 5 mg bid x 2 days, then 5 mg once daily x 1 day

**EFFICACY**

- Manufacturer is initiating phase III clinical trials in patients with severe COVID-19 to compare ruxolitinib to standard care.  
  - Dosage to be used in clinical trials for COVID-19.  

**ADVERSE EFFECTS/INTERACTIONS**

- **Adverse Effects:**
  - Most common adverse effects include thrombocytopenia, anemia, fatigue, diarrhea, bruising, dizziness, dyspnea, and headache
  - Severe withdrawal symptoms including a systemic inflammatory response syndrome have been reported when ruxolitinib was stopped

- **Drug Interactions:**
  - Strong CYP3A4 inhibitors can increase serum concentrations of ruxolitinib (ketoconazole increased ruxolitinib AUC by 91%)
  - Concurrent use of ruxolitinib with a strong CYP3A4 inhibitor should be avoided in patients with platelet counts less than 100 X 10^9/L; dosage reductions may be needed for patients with a platelet count ≥100 X 10^9/L

**COMMENTS**

- NIH recommends against use of JAK inhibitors, except in the context of a clinical trial, because of their broad immunosuppressive effect \(^1\) (updated 4/28/2020)
- Jakavi outside the US
- FDA-approved for treatment of myelofibrosis
- Inhibits JAK1 and 2, which mediate signaling of proinflammatory cytokines including IL-6; may mitigate the effects of cytokines release in response to the virus and limit lung damage in patients with severe disease
- Manufacturer initiating an open-label emergency Expanded Access Plan (EAP) in the US
- Should be avoided in patients with end stage renal disease (CrCl <15 mL/min) not requiring dialysis and in patients with moderate or severe renal impairment or hepatic impairment and a platelet count <100 X 10^9/L

**Pregnancy:**
- No adequate studies in pregnant women
- Administration of ruxolitinib to pregnant animals resulted in an increase in late resorptions and reduced fetal weights

---

2. Dosage to be used in clinical trials for COVID-19.
<table>
<thead>
<tr>
<th>DRUG AND DOSAGE</th>
<th>EFFICACY</th>
<th>ADVERSE EFFECTS/INTERACTIONS</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>TNF INHIBITORS</strong></td>
<td>▪ Optimal dosage for treatment of COVID-19 not established</td>
<td>▪ Injection-site reactions or infusion reactions (fever, urticaria, dyspnea, hypotension)</td>
<td>▪ Patients with COVID-19 have been found to have increased levels of inflammatory cytokines including TNF</td>
</tr>
<tr>
<td>(added 7/29/2020)</td>
<td>▪ Adalimumab (Humira)</td>
<td>▪ Cytopenias; malignancies, especially lymphomas, have been reported, but a cause-and-effect relationship has not been established</td>
<td>▪ TNF-inhibitors may mitigate the effects of cytokines released in response to the virus</td>
</tr>
<tr>
<td></td>
<td>▪ Certolizumab pegol (Cimzia)</td>
<td>▪ Increased risk of infections, including reactivated and disseminated tuberculosis, invasive or disseminated fungal infection, and other opportunistic infections; reactivation of HBV</td>
<td>▪ No clinical trial data yet available on efficacy of TNF inhibitors in patients with COVID-19</td>
</tr>
<tr>
<td></td>
<td>▪ Infliximab (Remicade, and biosimilars)</td>
<td>▪ Rarely induces or exacerbates heart failure or induces a reversible lupus-like syndrome</td>
<td></td>
</tr>
<tr>
<td></td>
<td>▪ Etanercept (Enbrel)</td>
<td>▪ Demyelinating conditions, including multiple sclerosis, optic neuritis, and Guillain-Barré syndrome have been reported</td>
<td></td>
</tr>
<tr>
<td></td>
<td>▪ Golimumab (Simponi)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Tnf Inhibitors**

*Brener et al. Gastroenterology 2020*

- **Population**: patients with inflammatory bowel disease (IBD) and COVID-19 (525 cases)
- **Design**: international (33 countries) registry to monitor outcomes of IBD patients with COVID-19 (Surveillance Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease (SECURE-IBD))
- **Results**: 31% hospitalized and 3% died
- **Risk factors for severe COVID-19 included corticosteroid and sulfasalazine or 5-aminosalicylate use, but not TNF-inhibitor use

**Limitations**: observational data

*Gianfrancesco et al. Ann Rheum Dis 2020*

- **Population**: patients with rheumatic disease and COVID-19 (600 cases)
- **Design**: international (40 countries) case series from the C19-GRA registry
- **Results**: 46% hospitalized and 9% died
- **Risk factors for hospitalization included corticosteroid use (prednisone dose ≥ 10 mg/day); TNF-inhibitor use was associated with reduced odds of hospitalization

**Limitations**: observational data

---

<table>
<thead>
<tr>
<th>DRUG AND DOSAGE</th>
<th>EFFICACY</th>
<th>ADVERSE EFFECTS/INTERACTIONS</th>
<th>COMMENTS</th>
</tr>
</thead>
</table>
| Anti-CD6 Monoclonal Antibody | **Biocon Trial – 2020**
Population: hospitalized patients with moderate to severe ARDS in 4 hospitals in India (n=30)
**Design:** Randomized, controlled, open-label trial
- 20 patients randomized to itolizumab plus best supportive care and 10 patients randomized to best supportive care
**Results:**
- at one month, no deaths occurred in patients treated with itolizumab and 3 deaths occurred in patients treated with supportive care alone
- reductions in IL-6 and TNF-α were reported in itolizumab-treated patients
**Limitation:** trial results not yet published | **Adverse Effects:**
- Infusion reactions including nausea, rash, urticaria, flushing, cough, wheezing, dyspnea, dizziness, headache; diarrhea
- Increased risk of infections
**Drug Interactions:**
- Live vaccines should be avoided | **Approved in India for emergency use in COVID-19 patients; also approved in India for psoriasis**
**Not available in the US**
**Anti-CD6 IgG1 monoclonal antibody that binds to the CD6 receptor and blocks activation of T lymphocytes; may mitigate the effects of cytokines released in response to the virus**
**Pregnancy:**
- No adequate data on use in pregnant women
- Crosses the placenta |

<table>
<thead>
<tr>
<th>DRUG AND DOSAGE</th>
<th>EFFICACY</th>
<th>ADVERSE EFFECTS/INTERACTIONS</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antimalarials</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CHLOROQUINE</strong>&lt;sup&gt;1&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>Updated 8/29/2020</em></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Dosage:</strong></td>
<td>Based on in vitro data (M Wang et al, Cell Res 2020)&lt;sup&gt;4&lt;/sup&gt;</td>
<td>Adverse Effects:</td>
<td>In vitro activity against SARS-CoV-2, SARS-CoV, and MERS-CoV</td>
</tr>
<tr>
<td></td>
<td>Unpublished clinical data from China&lt;sup&gt;3&lt;/sup&gt; in approximately 100 patients suggest more rapid decline in fever, improvement on lung CT scan, shorter time to recovery vs control group</td>
<td></td>
<td>FDA issued a Drug Safety Communication warning against use of chloroquine outside of a clinical trial because of the risk of serious cardiac arrhythmias, including QT prolongation; it is not recommended for treatment of outpatients&lt;sup&gt;5&lt;/sup&gt; <em>(updated 4/28/2020)</em></td>
</tr>
<tr>
<td></td>
<td>ChloroCovid-19&lt;sup&gt;5&lt;/sup&gt; <em>(updated 4/30/2020)</em></td>
<td>QT interval prolongation and arrhythmias, including torsades de pointes can occur. Risk is higher in patients with cardiac disease, electrolyte abnormalities, or concurrent use of other QT interval prolonging drugs such as azithromycin.&lt;sup&gt;6-8&lt;/sup&gt; The AHA/ACC/HRS recommend the drug be withheld in patients with baseline QT prolongation or if QT interval exceeds 500 msec during treatment. Potassium and magnesium levels should be corrected and other QTc prolonging drugs should be avoided.&lt;sup&gt;7&lt;/sup&gt;</td>
<td>Infectious Diseases Society of America recommends against use with or without azithromycin in the hospital setting&lt;sup&gt;12&lt;/sup&gt; <em>(updated 8/23/2020)</em></td>
</tr>
<tr>
<td></td>
<td>Population: hospitalized patients with severe illness in Brazil (n=81)</td>
<td>Cases (some fatal) of QT interval prolongation, ventricular tachycardia, and ventricular fibrillation have been reported in patients being treated with chloroquine or hydroxychloroquine, alone or in combination with azithromycin or other QTc prolonging drugs, for treatment of COVID-19&lt;sup&gt;9&lt;/sup&gt;</td>
<td>NIH guidelines recommend against use of chloroquine (with or without azithromycin) in hospitalized patients; in outpatients, they recommend against use, except in a clinical trial&lt;sup&gt;19&lt;/sup&gt; <em>(updated 8/29/2020)</em></td>
</tr>
<tr>
<td></td>
<td>Design:</td>
<td>Risk is higher in patients with cardiac disease, electrolyte abnormalities, or concurrent use of other QT interval prolonging drugs such as azithromycin.&lt;sup&gt;6-8&lt;/sup&gt; The AHA/ACC/HRS recommend the drug be withheld in patients with baseline QT prolongation or if QT interval exceeds 500 msec during treatment. Potassium and magnesium levels should be corrected and other QTc prolonging drugs should be avoided.&lt;sup&gt;7&lt;/sup&gt;</td>
<td>Clinical trials evaluating the efficacy and safety of chloroquine for pre-exposure and post-exposure prophylaxis and treatment of mild, moderate, or severe COVID-19 are underway in the US</td>
</tr>
<tr>
<td></td>
<td>parallel, double-blind, randomized, phase IIb</td>
<td></td>
<td>FDA revoked Emergency Use Authorization that allowed use in some hospitalized patients for whom a clinical trial was not feasible; ongoing analysis indicated that chloroquine and hydroxychloroquine are unlikely to be effective for treatment of COVID-19 and are associated with serious cardiac</td>
</tr>
<tr>
<td></td>
<td>chloroquine high dose (600 mg bid x 10 days) vs low dose (450 mg bid x 1 day, then once/day x 4 days); all patients received azithromycin</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Results:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Trial stopped early because of a higher rate of death and QT interval prolongation in the high-dose chloroquine group</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lethality was 39.0% (16 of 41) in the high-dosage group and 15.0% (6 of 40) in the low-dosage group at day 13</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>QTc interval &gt;500 milliseconds occurred in 18.9% (7 of 37) in the high-dose group compared to 11.1% (4 of 36) in the low-dosage group</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Respiratory secretion negative in 22.2% (6 of 27) at day 4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DRUG AND DOSAGE</td>
<td>EFFICACY</td>
<td>ADVERSE EFFECTS/INTERACTIONS</td>
<td>COMMENTS</td>
</tr>
<tr>
<td>-----------------</td>
<td>----------</td>
<td>-------------------------------</td>
<td>----------</td>
</tr>
<tr>
<td>CHLOROQUINE</td>
<td><strong>Mehra et al. 2020</strong>&lt;sup&gt;22&lt;/sup&gt; (added 5/26/20) (updated 6/4/2020)</td>
<td><strong>Drug Interactions:</strong></td>
<td>adverse events; FDA concluded benefit no longer outweighs risk&lt;sup&gt;13&lt;/sup&gt; (updated 6/16/2020)</td>
</tr>
<tr>
<td>(CONTINUED)</td>
<td><em><strong>Study Retracted&lt;sup&gt;24&lt;/sup&gt;</strong></em></td>
<td>▪ Avoid use with QTc prolonging drugs&lt;sup&gt;6-8&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>▪ Retracted because of concerns about the accuracy of the data and analysis; an independent audit was not possible because the full dataset was not made available</td>
<td>▪ Substrate of CYP2C8, 2D6, and 3A4, and inhibitor of CYP2D6&lt;sup&gt;10,11&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Population:</strong> hospitalized patients with COVID-19 who received chloroquine or HCQ with or without a macrolide within 48 hrs of diagnosis; control patients did not receive treatment with these drugs (n = 96,032)</td>
<td>▪ Use with antihyperglycemic drugs can increase risk of hypoglycemia</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Design:</strong> observational analysis of multinational registry</td>
<td><strong>Separate from antacids/kaolin by 4 hours</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Results:</strong> treatment was associated with an increased risk of in-hospital mortality and ventricular arrhythmia compared to control group</td>
<td><strong>Use with tamoxifen can increase risk of ocular toxicity and should be avoided</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Limitation:</strong> observational</td>
<td><strong>FDA warns that coadministration of remdesivir and chloroquine or hydroxychloroquine may decrease the antiviral activity of remdesivir; concurrent use is not recommended</strong>&lt;sup&gt;26&lt;/sup&gt; (added 6/18/2020)</td>
<td></td>
</tr>
<tr>
<td>HYDROXYCHLOROQUINE (HCQ)</td>
<td><strong>P Gautret et al. Int J Antimicrob Agents 2020</strong>&lt;sup&gt;14&lt;/sup&gt;</td>
<td><strong>Adverse Effects:</strong></td>
<td></td>
</tr>
<tr>
<td>(HCQ) – GENERICS</td>
<td><strong>Population:</strong> hospitalized patients; varying severity of illness (n=42)</td>
<td>▪ Better tolerated than chloroquine</td>
<td></td>
</tr>
<tr>
<td>PLAQUENIL (CONCORDIA)</td>
<td><strong>Design:</strong> open-label, observational</td>
<td>▪ Retinopathy and other ocular disorders (sometimes irreversible, but generally associated with longer use), serious cardiomyopathy, worsening of psoriasis and porphyria, proximal myopathy, neuropathy, suicidality, hypoglycemia</td>
<td></td>
</tr>
<tr>
<td>(updated 9/11/2020)</td>
<td>▪ HCQ + azithromycin vs HCQ vs standard care</td>
<td>▪ QT interval prolongation and arrhythmias, including torsades de pointes can occur.</td>
<td></td>
</tr>
<tr>
<td>Dosage:</td>
<td><strong>Results:</strong> HCQ-treated patients had more rapid viral clearance vs controls</td>
<td><strong>In vitro activity against SARS-CoV-2</strong></td>
<td></td>
</tr>
<tr>
<td>▪ Optimal dosage not established</td>
<td></td>
<td>The FDA issued a Drug Safety Communication warning against use of hydroxychloroquine outside of a clinical trial because of the risk of serious arrhythmias, including QT prolongation; it is not recommended for treatment of outpatients&lt;sup&gt;9&lt;/sup&gt; (updated 4/28/2020)</td>
<td></td>
</tr>
<tr>
<td>Dosages used in COVID-19 clinical trials have varied</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### DRUG AND DOSAGE

**HYDROXYCHLOROQUINE (CONTINUED)**

- Most frequently used dosage in the US has been 400 mg PO bid on day 1, then 200 mg PO bid x 4 days

### EFFICACY

- Addition of azithromycin to HCQ (n=6) resulted in a more rapid decrease in viral load compared to treatment w/ HCQ alone

**Limitations:**
- not randomized or double-blind, some dropouts not included in trial results
- International Society of Antimicrobial Chemotherapy states concerns about the paper

*Z Chen et al. 2020*[^15]

**Population:** hospitalized patients w/ pneumonia; mild illness (n=62)

**Design:**
- randomized, parallel-group
- hydroxychloroquine 200 mg bid vs standard care

**Results:**
- shortened duration of fever and cough
- pneumonia improvement on chest CT in 80.6% of patients w/ HCQ vs 54.8% w/ standard care
- 4 patients in control group progressed to severe illness vs none with HCQ

**Limitations:** published online ahead w/o peer review

* M Mahevas et al. 2020[^16]

**Population:** hospitalized patients with pneumonia requiring oxygen ≥2 L (n=181)

### ADVERSE EFFECTS/INTERACTIONS

Risk is higher in patients with pre-existing cardiac disease, electrolyte abnormalities or concurrent use of other QT interval prolonging drugs such as azithromycin. EKG monitoring recommended.

**AHA/ACC/HRS** recommend use be avoided in patients with baseline QT prolongation or if QT interval exceeds 500 msec during treatment. Potassium and magnesium levels should be corrected and other QTc prolonging drugs should be avoided.

**Risk is higher in patients with pre-existing cardiac disease, electrolyte abnormalities or concurrent use of other QT interval prolonging drugs such as azithromycin. EKG monitoring recommended.**[^6-8]

**Limitations:**
- not randomized or double-blind, some dropouts not included in trial results
- International Society of Antimicrobial Chemotherapy states concerns about the paper

**Z Chen et al. 2020**[^15]

**Population:** hospitalized patients w/ pneumonia; mild illness (n=62)

**Design:**
- randomized, parallel-group
- hydroxychloroquine 200 mg bid vs standard care

**Results:**
- shortened duration of fever and cough
- pneumonia improvement on chest CT in 80.6% of patients w/ HCQ vs 54.8% w/ standard care
- 4 patients in control group progressed to severe illness vs none with HCQ

**Limitations:** published online ahead w/o peer review

* M Mahevas et al. 2020[^16]

**Population:** hospitalized patients with pneumonia requiring oxygen ≥2 L (n=181)

**Drug Interactions:**
- Avoid use with other QT interval-prolonging drugs. Concurrent use with azithromycin can cause additive effects on the QT interval; avoid coadministration in patients at high risk of QT interval prolongation; ECG monitoring, correction of electrolyte abnormalities, and

### COMMENTS

- Infectious Diseases Society of America recommends against use with or without azithromycin in the hospital setting[^12] (updated 8/23/2020)

- NIH guidelines recommend against use of hydroxychloroquine (with or without azithromycin) in hospitalized patients; in outpatients, they recommend against use, except in a clinical trial[^19] (updated 8/29/2020)

- Some clinicians claim the combination of HCQ plus azithromycin is effective for early outpatient treatment of COVID-19, but randomized, controlled trials are lacking (added 9/10/2020)

- In one randomized controlled trial, hydroxychloroquine was not more effective than placebo for post-exposure prophylaxis; other trials are ongoing (added 7/17/2020)

- FDA revoked Emergency Use Authorization that allowed use in some hospitalized patients for whom a clinical trial was not feasible; ongoing analysis indicated that chloroquine and hydroxychloroquine are unlikely to be effective for treatment of COVID-19 and are associated with serious cardiac adverse events; FDA concluded benefit no longer outweighs risk[^13] (updated 6/16/2020)

### Pregnancy

- No evidence of increased rate of birth defects in pregnant women

[^6-8]: 6-8
[^15]: Z Chen et al. 2020
[^16]: M Mahevas et al. 2020
<table>
<thead>
<tr>
<th>DRUG AND DOSAGE</th>
<th>EFFICACY</th>
<th>ADVERSE EFFECTS/INTERACTIONS</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>HYDROXYCHLOROQUINE (CONTINUED)</td>
<td></td>
<td>avoidance of other QT prolonging agents is recommended if coadministered&lt;sup&gt;6-8&lt;/sup&gt;</td>
<td>Embryonic deaths and ocular malformations have occurred in pregnant rats</td>
</tr>
<tr>
<td>Design:</td>
<td>▪ Retrospective; HCQ 600 mg/day within 48 hrs of admission vs no HCQ</td>
<td>▪ May inhibit CYP2D6 and may be metabolized by CYP2C8, 2D6, and 3A4 to some extent; less likely to cause CYP-related interactions than chloroquine</td>
<td></td>
</tr>
<tr>
<td>Results:</td>
<td>▪ Transferred to ICU or died w/in 7 days: 20.2% HCQ vs 22.1% w/o HCQ (no significant difference)</td>
<td>▪ Separate from antacids/kaolin by 4 hours</td>
<td></td>
</tr>
<tr>
<td>Limitations:</td>
<td>▪ not randomized or peer reviewed</td>
<td>▪ May increase digoxin levels</td>
<td></td>
</tr>
</tbody>
</table>

**J Magagnoli et al 2020**<sup>17</sup> (<u>updated 4/28/2020</u>)

**Population:** hospitalized male patients in VA medical centers across the US (n=368)

**Design:**
▪ Retrospective; HCQ vs HCQ plus azithromycin vs no HCQ

**Results:**
▪ No significant difference in the rate of mechanical ventilation between groups (13.3% HCQ, 6.9% HCQ + azithromycin, and 14.1% no HCQ)
▪ Compared to no HCQ, rates of death higher in the HCQ group, but not the HCQ + azithromycin group (11.4% no HCQ vs 27.8% with HCQ and 22.1% with HCQ + azithromycin)

**Limitations:** retrospective, not peer reviewed

Avoidance of other QT prolonging agents is recommended if coadministered<sup>6-8</sup>

May inhibit CYP2D6 and may be metabolized by CYP2C8, 2D6, and 3A4 to some extent; less likely to cause CYP-related interactions than chloroquine

Separate from antacids/kaolin by 4 hours

May increase digoxin levels

May impair activity of antiepileptic drugs

FDA warns that coadministration of remdesivir and chloroquine or hydroxychloroquine may decrease the antiviral activity of remdesivir; concurrent use is not recommended<sup>26</sup> (<u>added 6/18/2020</u>)

Embryonic deaths and ocular malformations have occurred in pregnant rats
### Hydroxychloroquine (Continued)

<table>
<thead>
<tr>
<th>Drug and Dosage</th>
<th>Efficacy</th>
<th>Adverse Effects/Interactions</th>
<th>Comments</th>
</tr>
</thead>
</table>
| **J Geleris et al. NEJM 2020**<sup>20</sup>  
*Added 5/9/2020*  
**Population:** consecutive hospitalized patients (n=1376 patients in analysis)  
**Design:** observational; single medical center in New York City; median follow-up 22.5 days  
**Results:**  
▪ 811 (58.9%) patients treated with HCQ  
▪ HCQ-treated patients had more severe illness than those who were not treated with the drug  
▪ No significant association between HCQ use and intubation or death (HR 1.04; 95% CI 0.82-1.32)  
**Limitations:** observational data |
| **W Tang et al. BMJ 2020**<sup>21</sup>  
*Added 5/18/20*  
**Population:** hospitalized patients, mostly mild to moderate disease (n=150)  
**Design:** open-label HCQ 1200mg x 3 days, then 800 mg/day x2-3 weeks vs standard care  
**Results:**  
▪ No significant difference in probability of negative conversion  
▪ Adverse effects more common with HCQ (mainly diarrhea)  
**Limitations:** open label, tx initiated late, confounding tx allowed |
DRUG AND DOSAGE

HYDROXYCHLOROQUINE (CONTINUED)

Mehra et al. Lancet 2020\textsuperscript{22} (added 5/26/20)
(updated 6/4/20)

\textbf{Study Retracted}\textsuperscript{24}***

- Retracted because of concerns about the accuracy of the data and analysis; an independent audit was not possible because the full dataset was not made available

**Population:** hospitalized patients with COVID-19 who received chloroquine or HCQ with or without a macrolide within 48 hrs of diagnosis; control patients did not receive treatment with these drugs (n = 96,032)

**Design:** observational analysis of multinational registry

**Results:**
- treatment was associated with an increased risk of in-hospital mortality and ventricular arrhythmia compared to control group

**Limitation:** observational

\textbf{WHO Solidarity Trial 2020}\textsuperscript{23} (updated 6/20/2020)

- HCQ arm stopped based on data from the Solidarity trial, the RECOVERY trial, and a Cochrane review of other HCQ evidence
- Data showed no reduction of mortality with HCQ
<table>
<thead>
<tr>
<th>DRUG AND DOSAGE</th>
<th>EFFICACY</th>
<th>ADVERSE EFFECTS/INTERACTIONS</th>
<th>COMMENTS</th>
</tr>
</thead>
</table>
| HYDROXYCHLOROQUINE (CONTINUED) | **RECOVERY Trial 2020** *(added 6/20/2020)*  
**Population**: hospitalized adults in the UK *(n=4674)*  
**Design**: randomized controlled trial; HCQ vs usual care  
**Results**:  
▪ 28-day mortality was not significantly different between patients treated with HCQ and those who received usual care *(25.7% vs 23.5%)*  
▪ Enrollment in the HCQ arm of the trial has been stopped  
**Limitations**: data not yet published  | | | |
| | **S Arshad et al. Int J Infect Dis 2020** *(added July 7, 2020)*  
**Population**: Consecutive hospitalized patients in a hospital system in Michigan *(n=2541)*  
**Design**: Multi-center, retrospective observational study comparing hydroxychloroquine alone or with azithromycin, azithromycin alone or neither  
**Results**:  
▪ in-hospital mortality was 20.1% with hydroxychloroquine + azithromycin, 13.5% with hydroxychloroquine, 22.4% with azithromycin, and 26.4% with neither drug *(p<0.001)*  
▪ 82% of patients received hydroxychloroquine within 24 hours of admission  
**Limitations**: retrospective, observational data | | |

**Population:** symptomatic outpatients with COVID-19 or probable COVID-19 within 4 days of symptom onset (n=423)

**Design:** randomized, double-blind, placebo-controlled trial

- HCQ (800 mg once, 600 mg 6-8 hrs later, then 600 mg once/day x 4 days) vs placebo

**Results:**
- 81% had confirmed COVID-19 or exposure to a person with confirmed infection
- 56% enrolled within 1 day of symptom onset
- no significant difference in symptom severity over 14 days between HCQ and placebo groups (relative difference in symptom severity 12%; p=0.117)
- no significant difference in percentage of patients who had symptoms at 14 days (24% vs 30% with placebo; p=0.21)
- significantly more patients treated with HCQ had adverse effects (43% vs 22%; p<0.001)
- 4 hospitalizations and 1 nonhospitalized death in the HCQ group vs 10 hospitalizations and 1 hospitalized death in the placebo group (p=0.29)

**Limitations:** only 58% of patients received COVID-19 testing
<table>
<thead>
<tr>
<th>DRUG AND DOSAGE</th>
<th>EFFICACY</th>
<th>ADVERSE EFFECTS/INTERACTIONS</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>HYDROXYCHLOROQUINE (CONTINUED)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Rosenberg et al. JAMA 2020**<sup>30</sup> (added 7/22/2020)

**Population:** hospitalized patients

**Design:** retrospective multicenter cohort study

- HCQ plus azithromycin, HCQ alone, azithromycin alone, or neither

**Results:**

- Patients in the treatment groups had more severe disease at baseline than those not treated
- Compared with patients receiving neither drug, there was no difference in the in-hospital mortality rate in patients who received any of the 3 treatments
- Patients who received HCQ plus azithromycin had a higher risk of cardiac arrest compared to those who received neither drug

**Limitations:** observational data

**Cavalcanti et al. NEJM 2020**<sup>31</sup> (added 7/23/2020)

**Population:** hospitalized patients with suspected or confirmed COVID-19 receiving no supplemental oxygen or a max of 4 L/min (n=667 randomized; n=504 with confirmed COVID-19 in the modified intention-to-treat)

**Design:** open-label, multicenter randomized controlled trial

- HCQ 400 mg bid vs HCQ 400 mg bid plus azithromycin 500 mg once/day x 7 days vs standard care alone
HYDROXYCHLOROQUINE (CONTINUED)

Results:
▪ Treatment started a median of 7 days after symptom onset; patients who started treatment up to 14 days after symptom onset were included
▪ HCQ alone or with azithromycin did not improve clinical status at 15 days on an ordinal scale compared to standard care alone (primary endpoint in the modified intention-to-treat population, which included only those with confirmed COVID-19)
▪ QT interval prolongation and liver enzyme elevations occurred more frequently with HCQ with or without azithromycin than with standard care alone

Limitations: open-label trial, some patients previously received treatment

Mitja et al. Clin Infect Dis 2020
(added 9/9/2020)

Population: non-hospitalized adults in Spain with COVID-19 and <5 days of symptoms (n=293)

Design: open-label, randomized trial
▪ HCQ 800 mg x 1 day, then 400 mg once/day x 6 days vs no antiviral treatment (not placebo controlled)

Results:
▪ Median time from symptom onset to randomization: 3 days
▪ No significant difference in mean reduction of viral load at day 3 or at day 7
### HYDROXYCHLOROQUINE (CONTINUED)

#### EFFICACY
- Risk of hospitalization was not significantly different between the groups (5.9% HCQ vs 7.1% control)
- Time to resolution of symptoms was similar (10 days HCQ vs 12 days control; p=0.38) (study not powered for this endpoint)
- No cardiovascular events reported

#### ADVERSE EFFECTS/INTERACTIONS

#### MILLION ET AL. TRAVEL MED INFECT DIS 2020

**Population:** patients with mild (95% of patients) to severe COVID-19 in France (n=1061)

**Design:** retrospective analysis of outcomes of patients who were given early treatment with HCQ + azithromycin for ≥3 days

**Results:**
- Mean time from onset of symptoms to treatment was 6.4 days
- Good clinical outcome and virologic cure occurred in 973 patients (91.7%) within 10 days
- Poor clinical outcome (death, transfer to ICU, or hospitalization for >10 days) occurred in 46 patients (4.3%) and 10 patients (0.9%) died
- Poor clinical outcomes were associated with older age, illness severity, and low HCQ serum concentrations
<table>
<thead>
<tr>
<th>DRUG AND DOSAGE</th>
<th>EFFICACY</th>
<th>ADVERSE EFFECTS/INTERACTIONS</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>HYDROXYCHLOROQUINE (CONTINUED)</td>
<td>▪ 9 patients had QTc prolongation ≥ 60 ms from baseline; none were &gt; 500 ms</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Limitations:</strong> retrospective data, no control group; data incomplete for some patients</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Scholz, Derwand, Zelenko. 2020</strong>&lt;sup&gt;(added 9/10/2020) &lt;/sup&gt;</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Population:</strong> outpatients with COVID-19 (n=141)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Design:</strong> retrospective case series</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>▪ <strong>Cases</strong> received treatment with HCQ + azithromycin + zinc x 5 days after risk stratification criteria were met</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>▪ <strong>Untreated controls:</strong> independent public reference data from 337 patients with COVID-19 from the same community</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Results:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>▪ Treatment started after 4 days of symptom onset</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>▪ 4 of 141 (2.8%) treated patients were hospitalized; 58 of 377 (15.4%) controls were hospitalized (p&lt;0.001)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>▪ 1 of 141 (0.7%) treated patients died vs 13 of 377 (3.5%) controls (p=0.16)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Limitations:</strong> not peer reviewed; retrospective case series; risk criteria unclear; control group characteristics unclear</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DRUG AND DOSAGE</td>
<td>EFFICACY</td>
<td>ADVERSE EFFECTS/INTERACTIONS</td>
<td>COMMENTS</td>
</tr>
<tr>
<td>----------------</td>
<td>----------</td>
<td>------------------------------</td>
<td>----------</td>
</tr>
<tr>
<td>HYDROXYCHLOROQUINE (CONTINUED)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Barbosa Esper et al. 2020&lt;sup&gt;36&lt;/sup&gt; (added 9/11/2020)</td>
<td>Population: symptomatic outpatients with suspected COVID-19 evaluated by telemedicine in Brazil (n=636) Design: Prospective, observational ▪ patients given hydroxychloroquine plus azithromycin (n=412) were compared to those who refused medication (n=224) Results: ▪ mean time from symptom onset to treatment was 5 days ▪ 1.9% of treatment group required hospitalization compared to 5.4% of control group (p&lt;0.001) ▪ 1.17% of patients treated before day 7 of symptoms needed hospitalization compared to 3.2% of patients treated after day 7 Limitations: not peer reviewed, observational data</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PROPHYLAXIS TRIALS:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DR Boulware et al NEJM 2020&lt;sup&gt;25&lt;/sup&gt; (prophylaxis)</td>
<td>Population: adults with household or occupational exposure to an individual with confirmed COVID-19 at a distance &lt;6 feet for &gt;10 mins with no mask or eye shield (high-risk) or with a mask but no eye shield (moderate-risk) (n = 821)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DRUG AND DOSAGE</td>
<td>EFFICACY</td>
<td>ADVERSE EFFECTS/INTERACTIONS</td>
<td>COMMENTS</td>
</tr>
<tr>
<td>----------------</td>
<td>----------</td>
<td>------------------------------</td>
<td>----------</td>
</tr>
</tbody>
</table>
| HYDROXYCHLOROQUINE (CONTINUED) | **Design:** randomized, double-blind, placebo-controlled trial in the US and Canada  
Prophylaxis given within 4 days after exposure  
▪ HCQ (800 mg x 1, then 600 mg in 6 to 8 hrs, then 600 mg daily x 4 days) vs placebo  
**Results:**  
▪ 87.6% had a high-risk exposure  
▪ New illness compatible with COVID-19 within 14 days was similar between the 2 groups (11.8% HCQ vs 14.3% placebo; p=0.35)  
▪ Patient-reported adherence to study drug regimen was lower in HCQ group (75.4% with HCQ vs 82.6% with placebo; p=0.01)  
▪ Adverse effects occurred more often with HCQ (GI effects most common)  
▪ No arrhythmias or deaths reported  
**Limitations:** endpoint did not require laboratory-confirmed COVID-19; study population generally younger and healthier than those at most risk for COVID-19 | |

*N White and W Schilling et al (COPCOV trial)*[^27] *(added July 1, 2020)*  
(prophylaxis)  
**Population:** Healthcare workers and staff who have close contact with COVID-19 patients (anticipated enrollment is 40,000+ subjects)  
**Design:**  
▪ Randomized, double-blind, placebo-controlled, multi-center prophylaxis trial
<table>
<thead>
<tr>
<th>DRUG AND DOSAGE</th>
<th>EFFICACY</th>
<th>ADVERSE EFFECTS/INTERACTIONS</th>
<th>COMMENTS</th>
</tr>
</thead>
</table>
| HYDROXYCHLOROQUINE (CONTINUED) | ▪ Chloroquine/hydroxychloroquine vs placebo  
   **Results:** trial enrolling as of July 2020 |  |  |
|  |  | Mitja et al. medRxiv 2020[32](added 7/31/2020)  
   **Population:** asymptomatic contacts exposed to a PCR-positive COVID-19 case in Spain (n=2314)  
   **Design:** open-label, cluster-randomized trial  
   ▪ HCQ 800 mg once, then 400 mg/day x 6 days vs no therapy  
   **Results:** PCR-confirmed symptomatic COVID-19 within 14 days was not statistically significant between the two groups (5.7% with HCQ vs 6.2% with usual care)  
   **Limitations:** not peer reviewed |  |

1. FDA-approved for other indications.
2. Experimental dosage used for treatment of COVID-19 in trials, but optimal dosage not yet established.
<table>
<thead>
<tr>
<th>DRUG AND DOSAGE</th>
<th>EFFICACY</th>
<th>ADVERSE EFFECTS/INTERACTIONS</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>DRUG AND DOSAGE</td>
<td>EFFICACY</td>
<td>ADVERSE EFFECTS/INTERACTIONS</td>
<td>COMMENTS</td>
</tr>
<tr>
<td>-----------------</td>
<td>----------</td>
<td>-----------------------------</td>
<td>----------</td>
</tr>
<tr>
<td><strong>Macrolide Antibiotic</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>AZITHROMYCIN – GENERICS</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ZITHROMAX (PFIZER)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>(updated 9/18/2020)</em></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Dosage:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Optimal dosage not established</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>500 mg on day 1, then 250 mg once/day on days 2-5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>In addition to hydroxychloroquine</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>P Gautret et al. <em>Int J Antimicrob Agents</em> 2020</td>
<td></td>
<td>In vitro activity against some viruses (influenza A H1N1 and Zika); no data on its activity against SARS-CoV-2</td>
</tr>
<tr>
<td></td>
<td>Rosenberg et al. <em>JAMA</em> 2020</td>
<td></td>
<td>Minimal data supporting efficacy in COVID-19 in humans and cardiac toxicity can occur when used with chloroquine/hydroxychloroquine</td>
</tr>
<tr>
<td></td>
<td><em>Population</em>: hospitalized patients&lt;br&gt;<em>Design</em>: retrospective multicenter cohort study&lt;br&gt;<em>HCQ plus azithromycin, HCQ alone, azithromycin alone, or neither</em></td>
<td></td>
<td>Infectious Diseases Society of America recommends against use with chloroquine or hydroxychloroquine in the hospital setting</td>
</tr>
<tr>
<td></td>
<td><em>Results</em>: &lt;br&gt; Patients in the treatment groups had more severe disease at baseline than those not treated&lt;br&gt; Compared with patients receiving neither drug, there was no difference in the in-hospital mortality rate in patients who received any of the 3 treatments&lt;br&gt; Patients who received HCQ plus azithromycin had a higher risk of cardiac arrest compared to those who received neither drug</td>
<td></td>
<td>NIH guidelines recommend against use of hydroxychloroquine or chloroquine with or without azithromycin in hospitalized patients; in outpatients, they recommend against use, except in a clinical trial <em>(updated 8/29/2020)</em></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Some evidence of immunomodulatory and anti-inflammatory activity; it has been used as adjunctive treatment for other respiratory conditions (such as COPD)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Pregnancy: No evidence of fetal harm</td>
</tr>
</tbody>
</table>

**Adverse Effects:**
- GI disturbances, headache, dizziness, hepatotoxicity, QT prolongation

**Drug Interactions:**
- Use with other drugs that prolong the QT interval (such as chloroquine and hydroxychloroquine) can result in additive effects; avoid coadministration in patients at high risk of QT interval prolongation; ECG monitoring, correction of electrolyte abnormalities, and avoidance of other QT prolonging agents is recommended if coadministered

- In a cohort of 84 patients with COVID-19 who were treated with hydroxychloroquine/azithromycin, QTc was significantly prolonged; in 9 (11%) patients, QTc was prolonged to >500 ms

- May increase the risk of toxicity with digoxin, cyclosporine, tacrolimus
<table>
<thead>
<tr>
<th>DRUG AND DOSAGE</th>
<th>EFFICACY</th>
<th>ADVERSE EFFECTS/INTERACTIONS</th>
<th>COMMENTS</th>
</tr>
</thead>
</table>
| AZITHROMYCIN (continued) | **S Arshad et al. Int J Infect Dis 2020**¹¹ *(added July 7, 2020)*  
**Population:** Consecutive hospitalized patients in a hospital system in Michigan (n=2541)  
**Design:** Multi-center, retrospective observational study comparing hydroxychloroquine alone or with azithromycin, azithromycin alone or neither  
**Results:**  
- in-hospital mortality was 20.1% with hydroxychloroquine + azithromycin, 13.5% with hydroxychloroquine, 22.4% with azithromycin, and 26.4% with neither drug (p<0.001)  
- 82% of patients received hydroxychloroquine within 24 hours of admission  
**Limitations:** retrospective, observational data | | |
| | **Mehra et al. Lancet 2020**¹² *(added 5/26/20)*  
*(updated 6/4/20)*  
**Study Retracted**¹³  
* Retracted because of concerns about the accuracy of the data and analysis; an independent audit was not possible because the full dataset was not made available  
**Population:** hospitalized patients with COVID-19 who received chloroquine or HCQ with or without a macrolide within 48 hrs of diagnosis; control patients did not receive treatment with these drugs (n = 96,032) | | |
<table>
<thead>
<tr>
<th>DRUG AND DOSAGE</th>
<th>EFFICACY</th>
<th>ADVERSE EFFECTS/INTERACTIONS</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>AZITHROMYCIN (continued)</td>
<td><strong>Design:</strong> observational analysis of multinational registry&lt;br&gt;<strong>Results:</strong>&lt;br&gt;▪ treatment was associated with an increased risk of in-hospital mortality and ventricular arrhythmia compared to control group&lt;br&gt;<strong>Limitation:</strong> observational&lt;br&gt;<strong>J Magagnoli et al 2020</strong>&lt;sup&gt;14&lt;/sup&gt; <em>(updated 4/28/2020)</em>&lt;br&gt;<strong>Population:</strong> hospitalized male patients in VA medical centers across the US (n=368)&lt;br&gt;<strong>Design:</strong>&lt;br&gt;▪ Retrospective; HCQ vs HCQ plus azithromycin vs no HCQ&lt;br&gt;<strong>Results:</strong>&lt;br&gt;▪ No significant difference in the rate of mechanical ventilation between groups (13.3% HCQ, 6.9% HCQ + azithromycin, and 14.1% no HCQ)&lt;br&gt;▪ Compared to no HCQ, rates of death higher in the HCQ group, but not the HCQ + azithromycin group (11.4% no HCQ vs 27.8% with HCQ and 22.1% with HCQ + azithromycin)&lt;br&gt;<strong>Limitations:</strong> retrospective, not peer reviewed</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DRUG AND DOSAGE</td>
<td>EFFICACY</td>
<td>ADVERSE EFFECTS/INTERACTIONS</td>
<td>COMMENTS</td>
</tr>
<tr>
<td>-----------------</td>
<td>----------</td>
<td>-------------------------------</td>
<td>----------</td>
</tr>
<tr>
<td><strong>AZITHROMYCIN (continued)</strong></td>
<td><strong>Cavalcanti et al. NEJM 2020</strong>&lt;sup&gt;15&lt;/sup&gt; (added 7/23/2020)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Population:</strong> hospitalized patients with suspected or confirmed COVID-19 receiving no supplemental oxygen or a max of 4 L/min (n=667 randomized; n=504 with confirmed COVID-19 in the modified intention-to-treat)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Design:</strong> open-label, multicenter randomized controlled trial</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>▪ HCQ 400 mg bid vs HCQ 400 mg bid plus azithromycin 500 mg once/day x 7 days vs standard care alone</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Results:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>▪ Treatment started a median of 7 days after symptom onset; patients who started treatment up to 14 days after symptom onset were included</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>▪ HCQ alone or with azithromycin did not improve clinical status at 15 days on an ordinal scale compared to standard care alone (primary endpoint in the modified intention-to-treat population, which included only those with confirmed COVID-19)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>▪ QT interval prolongation and liver enzyme elevations occurred more frequently with HCQ with or without azithromycin than with standard care alone</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Limitations:</strong> open-label trial, some patients previously received treatment</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DRUG AND DOSAGE</td>
<td>EFFICACY</td>
<td>ADVERSE EFFECTS/INTERACTIONS</td>
<td>COMMENTS</td>
</tr>
<tr>
<td>-----------------</td>
<td>----------</td>
<td>-------------------------------</td>
<td>----------</td>
</tr>
<tr>
<td><strong>AZITHROMYCIN (continued)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Barbosa Esper et al. 2020

**Population:** symptomatic outpatients with suspected COVID-19 evaluated by telemedicine in Brazil (n=636)

**Design:** Prospective, observational

- patients given hydroxychloroquine plus azithromycin (n=412) were compared to those who refused medication (n=224)

**Results:**
- mean time from symptom onset to treatment was 5 days
- 1.9% of treatment group required hospitalization compared to 5.4% of control group (p<0.001)
- 1.17% of patients treated before day 7 of symptoms needed hospitalization compared to 3.2% of patients treated after day 7

**Limitations:** not peer reviewed, observational data

### RHM Furtado et al Lancet 2020

**Population:** hospitalized patients in Brazil with severe disease (requiring >4 L/min supplemental oxygen, high-flow nasal cannula, non-invasive mechanical ventilation, or invasive mechanical ventilation) (n=447; n=397 in mITT with confirmed COVID)

**Design:** open-label, randomized trial

- azithromycin plus standard care (which included HCQ) vs standard care alone
### AZITHROMYCIN (continued)

#### DRUG AND DOSAGE

- **Azithromycin**

#### EFFICACY

**Results:**
- Clinical status measured on an ordinal scale at day 15 was similar between the two groups
- Adverse events, including cardiac arrhythmias, were not significantly different between groups

**Limitations:**
- Open-label; high-risk population; some patients in control group received macrolide during trial

#### ADVERSE EFFECTS/INTERACTIONS

- **Respiratory:**
  - Nausea
  - Vomiting
  - Diarrhea
  - abdominal pain
  - Urticaria
  - Rash
  - Pruritus
  - Erythema multiforme
  - Maculopapular rash
  - Other skin disorders
  - Drug fever
  - Anaphylactic reaction
  - Rash/urticaria
  - Hemorrhagic rash
  - Stevens-Johnson syndrome

#### COMMENTS

1. FDA-approved for other indications.
2. Experimental dosage used for treatment of COVID-19 in trials, but optimal dosage not yet established.
5. DN Juurlink. Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection. CMAJ 2020 April 8 (epub).
### HIV Protease Inhibitors

<table>
<thead>
<tr>
<th><strong>Drug and Dosage</strong></th>
<th><strong>Efficacy</strong></th>
<th><strong>Adverse Effects/Interactions</strong></th>
<th><strong>Comments</strong></th>
</tr>
</thead>
</table>
| **Atazanavir (ATV)** - **Reyataz (BMS) and Generics** | ▪ Predicted to inhibit SARS-CoV-2 replication<sup>3,4</sup> | **Adverse Effects:**  
▪ Nausea, diarrhea, asymptomatic indirect hyperbilirubinemia, rash, nephrolithiasis, cholelithiasis, PR interval prolongation  
**Drug Interactions:**  
▪ Substrate of CYP3A4 and inhibitor of CYP3A4 and CYP2C8<sup>5</sup>  
▪ Use of drugs that increase gastric pH, such as PPIs, H2-antihistamines, and antacids may decrease absorption of atazanavir; administer atazanavir 2 hours before or 10 hours after an H2-antihistimine; consider avoiding use of PPIs | ▪ No clinical trials available evaluating use of atazanavir for COVID-19  
▪ Available in powder form or capsules can be opened for administration via enteral tube  
▪ NIH recommends against use of HIV protease inhibitors, except in the context of a clinical trial, because of unfavorable pharmacodynamics and negative clinical trial data<sup>6</sup>  
▪ Pregnancy:  
▪ Does not appear to increase the risk of major birth defects |
| **Dosage:**  
▪ Optimal dosage/duration not established  
▪ 300-400 mg PO once/day<sup>2</sup> |  |  |  |

| **DARUNAVIR/Cobicistat (PrezcoBix)**  
**Shanghai Public Health Clinical Center (SPHCC)**<sup>8,9</sup>  
**Population:** hospitalized patients (n=30)  
**Design:** randomized, open label  
**Results:** darunavir/cobicistat 800/150 mg once/day x 5 days vs standard care | **Adverse Effects:**  
▪ Nausea, diarrhea, increased transaminases, headache, rash, severe skin reactions (including Stevens-Johnson syndrome)  
**Drug Interactions:**  
▪ Substrate and inhibitor of CYP3A4 and CYP2D6<sup>5</sup> | ▪ An initial laboratory study had suggested darunavir (at exposures higher than those achieved in humans) may be effective against SARS-CoV-2  
▪ No evidence that darunavir is effective for treatment of COVID-19  
▪ NIH recommends against use of HIV protease inhibitors, except in the context of a clinical trial, because of unfavorable pharmacodynamics and negative clinical trial data<sup>6</sup>  
▪ Pregnancy:  
▪ Not recommended for use in pregnant women |  |
| **Dosage:**  
800/150 mg  
PO once/day x 5 days<sup>7</sup> |  |  |  |
**DRUG AND DOSAGE**

**LOPINAVIR/RITONAVIR**

*– KALETRA (ABBVIE)*

**Dosage:**
- Optimal dosage/duration not established
- Dosages/duration/concomitant drugs used in COVID-19 clinical trials have varied
- 400/100 mg PO bid
- With or without food
- Tablets should not be crushed (decrease exposure)

<table>
<thead>
<tr>
<th>EFFICACY</th>
<th>ADVERSE EFFECTS/INTERACTIONS</th>
<th>COMMENTS</th>
</tr>
</thead>
</table>

**B Cao et al. NEJM 2020**

**Population:**
- hospitalized patients w/pneumonia, SaO₂ ≤94% or PaO₂:FiO₂ ≤300 mm Hg (n=199)
- median time from symptom onset to randomization was 13 days

**Design:**
- randomized, open-label vs standard care

**Results:**
- no statistically significant difference in time to clinical improvement (median of 16 days in both groups), time to discharge (median 12 days with LPV/RTV vs 14 days with standard care), mortality (19.2% vs 25.0%), or viral load reduction

**Limitations:**
- not blinded
- treatment started long after symptom onset


**Population:**
- hospitalized patients admitted to “normal care” ward (n=8)

**Design:**
- case series; pharmacokinetic analysis

**Results:**
- median trough lopinavir concentrations 13.6 mcg/mL
- to achieve half-maximal effective concentration (EC₅₀) for SARS-CoV-2, lopinavir trough concentrations

**Adverse Effects:**
- Diarrhea, nausea, vomiting, headache, asthenia, hepatotoxicity, pancreatitis, PR and QT interval prolongation, bradycardia

**Drug Interactions:**
- Substrate and inhibitor of CYP3A4
- Avoid use with other PR or QT interval-prolonging drugs

- *In vitro* activity against SARS-CoV, and MERS-CoV; data in SARS-CoV-2 limited
- Society of Critical Care Medicine recommends against use of LPV/RTV in critically ill patients
- Infectious Diseases Society of America recommends use only in the context of a clinical trial
- NIH recommends against use of HIV protease inhibitors, except in the context of a clinical trial, because of unfavorable pharmacodynamics and negative clinical trial data
- No association with teratogenic effects; may be associated with preterm delivery

**Pregnancy:**
<table>
<thead>
<tr>
<th>DRUG AND DOSAGE</th>
<th>EFFICACY</th>
<th>ADVERSE EFFECTS/INTERACTIONS</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>LOPINAVIR/RITONAVIR (continued)</strong></td>
<td>would need to be 60- to 120-fold higher</td>
<td><strong>Limitations:</strong> small case series; only trough concentration evaluated; no <em>in vivo</em> data on EC$_{50}$ dose of lopinavir for SARS-CoV-2</td>
<td>FDA-approved for other indications.</td>
</tr>
</tbody>
</table>

# DRUG AND DOSAGE

## EFFICACY

<table>
<thead>
<tr>
<th>Drug and Dosage</th>
<th>Efficacy</th>
<th>Adverse Effects/Interactions</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interferon Beta and Ribavirin</td>
<td>Interferon Beta-1B — Betaseron Extavia</td>
<td><strong>Population:</strong> hospitalized patients with symptom duration ≤14 days (n=127)</td>
<td><strong>Has antiviral properties</strong></td>
</tr>
<tr>
<td>Ribavirin — Rebetol, and Generics</td>
<td><strong>Design:</strong> prospective, randomized, open-label, multi-center</td>
<td><strong>In vitro</strong> activity against SARS-CoV and MERS-CoV, but did not appear to improve disease outcomes in human studies²</td>
<td></td>
</tr>
<tr>
<td><strong>Dosage:</strong></td>
<td>▪ Optimal dosage unknown</td>
<td><strong>Society of Critical Care Medicine recommends against use of LPV/RTV in critically ill patients and states the evidence is insufficient to recommend interferons or ribavirin³</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>▪ Dosage used in clinical trial: Interferon beta-1b: 1 mL on alternate days x 1-3 doses depending on day of initiation</td>
<td><strong>NIH guidelines recommend against use of interferons in patients with severe or critical illness, except in a clinical trial; they state there are insufficient data to recommend for or against use in patients with early (&lt;7 days from symptom onset) mild and moderate illness</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ribavirin: 400 mg q12h x 14 days</td>
<td><strong>If administered, should be given early in course of disease</strong></td>
<td></td>
</tr>
</tbody>
</table>

## Adverse Effects:

- Hung et al trial found no difference in adverse events between 2 groups

## Interferon: injection- depression site reactions, flu-like symptoms, transaminase elevations, possible cardiac toxicity, autoimmune disorders, allergic reactions, hepatotoxicity, seizures, suicidal ideation, lymphopenia

## Ribavirin: hemolytic anemia, leukopenia, cough, dyspnea, bronchospasm, rash, conjunctival irritation, neuropsychologic symptoms

## Drug Interactions:

- May decrease anticoagulant effect of warfarin, increase concentrations of azathioprine, increased risk of hepatic decompensation and lactic acidosis with NRTIs, additive myelosuppression with interferons, linezolid, clozapine, adalimumab

## Pregnant women and in men whose partners are pregnant

## Pregnancy:

- Interferon: may cause fetal harm, based on data from animal studies

- Ribavirin: contraindicated in pregnant women and in men whose partners are pregnant

- Pregnancy should be avoided for 6 months after treatment in women who received the drug and in women whose partners received the drug

## Comments

- Society of Critical Care Medicine recommends against use of LPV/RTV in critically ill patients and states the evidence is insufficient to recommend interferons or ribavirin³

- NIH guidelines recommend against use of interferons in patients with severe or critical illness, except in a clinical trial; they state there are insufficient data to recommend for or against use in patients with early (<7 days from symptom onset) mild and moderate illness

- If administered, should be given early in course of disease

- Nebulized interferon not available in the US (added 7/20/2020)

- Has antiviral properties
**INTERFERON BETA-1B – BETASERON (continued)**

<table>
<thead>
<tr>
<th>DRUG AND DOSAGE</th>
<th>EFFICACY</th>
<th>ADVERSE EFFECTS/INTERACTIONS</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Development of severe disease (requiring ventilation or death) was less likely with interferon than with placebo (OR 0.21; 95% CI 0.04-0.97; ( p=0.046 ))</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Recovery (no limitation of activities or no evidence of infection) was more likely with interferon (HR 2.19; 95% CI 1.03-4.69; ( p=0.043 ))</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Breathlessness reduced in patients receiving interferon compared to placebo (( p=0.007 ))</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0 deaths with interferon; 3 deaths with placebo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>In patients with more severe disease on admission (requiring supplemental oxygen), interferon nonsignificantly increased the likelihood of hospital discharge (( p=0.096 ))</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median time to discharge was 6 days with interferon and 9 days with placebo</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Limitations:** phase 2 trial; data not yet published

---

<table>
<thead>
<tr>
<th>DRUG AND DOSAGE</th>
<th>EFFICACY</th>
<th>ADVERSE EFFECTS/INTERACTIONS</th>
<th>COMMENTS</th>
</tr>
</thead>
</table>
| **Antiparasitic** | ▪ Inhibits SARS-CoV-2 *in vitro*; ~5000-fold reduction in viral RNA in cell culture 48 hours after a single treatment2  
Rajter et al. MedRxiv 20205 (added 8/29/2020)  
**Population:** hospitalized patients (n=280)  
**Design:** retrospective cohort; ivermectin compared to usual care  
▪ 200 mcg/kg x 1 dose, 2nd dose given after 7 days if still hospitalized  
**Results:**  
▪ All-cause mortality was 15.0% with ivermectin and 25.2% with usual care group (p=0.03); difference remained significant after adjustment (OR 0.27; p=0.03)  
▪ In 75 patients with severe pulmonary disease, mortality was lower with ivermectin (38.8% vs 80.7%, p=0.001)  
▪ No significant difference in extubation rates (36.1% vs 15.4%, p=0.07)  
**Limitations:** retrospective data; not peer reviewed; unclear what other treatments patients received; intervention timing not standardized | ▪ Generally well tolerated when used for treatment of lice; diarrhea has occurred  
▪ Diarrhea, nausea, dizziness, pruritis, dermatologic reactions, lymphadenitis, arthralgia, and fever have been reported when used for treatment of onchocerciasis  
**Drug Interactions:**  
▪ Azithromycin may increase serum concentrations of ivermectin  
**Adverse Effects:**  
▪ FDA-approved for treatment of intestinal strongyloidiasis and onchocerciasis; used off-label for a variety of other parasitic infections including lice and scabies  
▪ Inhibited SARS-CoV-2 *in vitro*; may inhibit nuclear transport activity  
▪ NIH guidelines recommend against use, except in a clinical trial3 (updated 8/29/2020)  
▪ FDA warns against human use of ivermectin intended for use in animals4  | • FDA-approved for treatment of intestinal strongyloidiasis and onchocerciasis; used off-label for a variety of other parasitic infections including lice and scabies  
• Inhibited SARS-CoV-2 *in vitro*; may inhibit nuclear transport activity  
• NIH guidelines recommend against use, except in a clinical trial3 (updated 8/29/2020)  
• FDA warns against human use of ivermectin intended for use in animals4  |

1. Dosage for other indications. For some indications only a single dose is required, but for others the dose may need to be repeated 2-3 times.
<table>
<thead>
<tr>
<th>DRUG AND DOSAGE</th>
<th>EFFICACY</th>
<th>ADVERSE EFFECTS/INTERACTIONS</th>
<th>COMMENTS</th>
</tr>
</thead>
</table>
| **Bradykinin Inhibitor** | van de Veerdonk et al. JAMA Netw Open 2020<sup>1</sup>  
**Population:** hospitalized patients with confirmed COVID-19 in the Netherlands (n=27; 9 cases/18 controls)  
**Design:** case-control study  
**Results:**  
- icatibant-treated patients required less oxygen supplementation vs controls  
- 4 of 9 patients given icatibant were no longer oxygen dependent within 10-35 hours  
- 8 of 9 had a reduction of oxygen requirements ≥3 L/min after 24 hrs with icatibant vs 3 of 18 controls  
- 3 patients had a resurgence in need for oxygen supplementation; possibly due to short half-life of icatibant  
**Limitations:** retrospective data; 9 cases |  
**Adverse Effects:**  
- Injection site reactions, pyrexia, transaminase increases, dizziness, rash  
**Drug Interactions:**  
- May attenuate antihypertensive effect of ACE inhibitors |  
- FDA-approved for treatment of acute attacks of hereditary angioedema (HAE)  
- SARS-CoV-2 enters cells via ACE2, which breaks down bradykinin; loss of ACE2 may result in stimulation of the bradykinin 2 receptor, which could be a contributing factor in pulmonary edema in patients with COVID-19  
- Icatibant is a competitive antagonist selective for the bradykinin B2 receptor  
- Icatibant use has not been associated with a risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes based on available data from published literature and the pharmacovigilance database  
- Adverse maternal and fetal outcomes have been reported in animal studies |

---

<table>
<thead>
<tr>
<th>DRUG AND DOSAGE</th>
<th>EFFICACY</th>
<th>ADVERSE EFFECTS/INTERACTIONS</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Colchicine</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**GRECCO-19 trial**<sup>1</sup>

- **Population**: Hospitalized patients (n=105)
- **Design**: Randomized, open-label trial in Greece
- Colchicine plus standard of care vs standard of care alone x 3 weeks

**Results**: Differences in inflammatory biomarkers (high sensitivity cardiac troponin, C-reactive protein) were not statistically significant between groups.

- The clinical primary endpoint (time from baseline to clinical deterioration, defined as a 2-grade increase on a 7 point scale) occurred in 7 patients (14.0%) in the control group and in 1 patient (1.8%) in the colchicine group (p = 0.02)

**Limitations**: Small, open-label trial

- Almost all patients also received treatment with hydroxychloroquine and azithromycin or lopinavir/ritonavir

**Adverse Effects**:<sup>2</sup>

- Diarrhea, nausea, and vomiting are common with use of colchicine.
- Blood dyscrasias have been reported.
- Neuromyopathy is rare; it typically occurs in elderly patients or in those with hepatic or renal impairment.
- Overdosage of colchicine can be fatal.

**Drug Interactions**: Substrate of CYP3A4 and the efflux transporter P-glycoprotein (P-gp); fatalities have been reported rarely in patients taking colchicine with a strong CYP3A4 inhibitor such as clarithromycin or a strong P-gp inhibitor such as cyclosporine.

- Dosage should be reduced when colchicine is taken concurrently with or within 2 weeks after a CYP3A4 or P-gp inhibitor
- Myopathy and rhabdomyolysis have occurred in patients taking colchicine with a statin or a fibrate

**Comments**: Colchicine has anti-inflammatory properties.

- More trials are ongoing to evaluate the efficacy of colchicine for treatment of COVID-19
- Embryofetal toxicity and teratogenicity and altered postnatal development reported in animal studies

**Pregnancy**: No adequate studies in pregnant women

---

### Dipeptidyl Peptidase-4 (DPP-4) Inhibitors

<table>
<thead>
<tr>
<th><strong>ALOGLIPTIN – NESINA</strong></th>
<th><strong>LINAGLIPTIN – TRADJENTA</strong></th>
<th><strong>SAXAGLIPTIN – ONGLYZA</strong></th>
<th><strong>SITAGLIPTIN – JANUVIA</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Dosage:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>▪ Optimal dosage in patients with COVID-19 is unclear</td>
<td>▪ Dosage adjustments are needed for reduced renal function</td>
<td>▪ Usual dosage for treatment of type 2 diabetes:</td>
<td>▪ (Added 5/12/2020)</td>
</tr>
<tr>
<td>▪ Alogliptin: 25 mg PO once/day</td>
<td>▪ Linagliptin: 5 mg PO once/day</td>
<td>▪ Saxagliptin: 2.5-5 mg PO once/day</td>
<td>▪ Sitagliptin: 100 mg PO once/day</td>
</tr>
</tbody>
</table>

**Efficacy**
- Clinical trials with linagliptin in patients with type 2 diabetes and mild or moderate COVID-19 are expected to begin to determine if use of the drug can improve glucose control and reduce the severity of COVID-19<sup>1,2</sup>

**Adverse Effects:**
- Acute pancreatitis, fatal hepatic failure, possible worsening of heart failure, possible severe and disabling joint pain

**Drug Interactions:**
- Strong P-glycoprotein or CYP3A4 inducers<sup>5</sup> can decrease serum concentrations of linagliptin; concurrent use should be avoided if possible
- Strong CYP3A4/5 inhibitors<sup>5</sup> can increase saxagliptin concentrations; the dose of saxagliptin should not exceed 2.5 mg when used in combination with a CYP3A4/5 inhibitor
- Sitagliptin may increase digoxin concentrations; monitor patients taking digoxin

**Comments**
- Hypothesized that inhibition of DPP-4 may prevent infection with or progression of COVID-19
- Mechanism not established, but it has been suggested that DPP-4 may be involved in SARS-CoV-2 cell adhesion and DPP-4 inhibitors may have effects on inflammation<sup>3,4</sup>
- Pregnancy:
  - Limited data on use during pregnancy; insulin is generally preferred in pregnant women

---


<table>
<thead>
<tr>
<th>DRUG AND DOSAGE</th>
<th>EFFICACY</th>
<th>ADVERSE EFFECTS/INTERACTIONS</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>DAPAGLIFLOZIN – FARXIGA (ASTRAZENECA) (Updated 4/28/2020)</td>
<td>Phase III trial (DARE-19) ongoing in the US and Europe in hospitalized patients with cardiovascular (CV), metabolic, or renal risk factors</td>
<td>Adverse Effects:</td>
<td>Some experts have advised that SGLT2 inhibitors be stopped in hospitalized COVID-19 patients because of increased risk of DKA and have concerns with the conduction of the DARE-19 trial</td>
</tr>
<tr>
<td>Dosage:</td>
<td>▪ 10 mg once/day</td>
<td>▪ Genital mycotic and urinary tract infections, acute kidney injury, volume depletion, hypotension, and ketoacidosis</td>
<td>▪ SGLT2 inhibitors have been shown to have beneficial effects in patients with cardiovascular and renal comorbidities not infected with COVID-19; hypothesized that they may also have protective effects in patients with COVID-19</td>
</tr>
</tbody>
</table>

**Drug Interactions:**
- Metabolized primarily by UGT1A9; mefenamic acid (Ponstel), a UGT1A9 inhibitor, increased dapagliflozin AUC by about 50%, but dapagliflozin dosage reduction not needed
- Taking dapagliflozin with insulin or a sulfonylurea increases the risk of hypoglycemia

**Mechanism not established, but SGLT2 inhibitors may have favorable effects on mechanisms involved in respiratory failure, sepsis, and multi-organ failure/cytokine storm**

**Pregnancy:**
- Not recommended during the second and third trimester; adverse renal effects have been reported in animal studies

---

# H2-Receptor Antagonists (H2RAs)

## Famotidine – Pepticid (VALEANT)  
*(Updated 9/21/2020)*

<table>
<thead>
<tr>
<th><strong>Dosage:</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical trial administering high-dose IV treatment (120 mg IV q8h)</td>
</tr>
</tbody>
</table>

### Efficacy
- Ongoing trial in New York
- Review of patient records from China suggested that use of famotidine was associated with a lower death rate compared to those not taking the drug (Science April 26, 2020)

**DE Freedberg et al.**  
*Gastroenterology 2020*¹ *(updated 6/5/2020)*  
**Population:** hospitalized, non-intubated, non-ICU (n=1620)  
**Design:** Retrospective cohort, famotidine vs no famotidine  
**Results:**  
- Reduced risk for death or intubation (adjusted HR 0.42)  
- PPI use not associated with lower risk  
- 5.1% of patients were given famotidine within 24 hours of admission  
**Limitations:** observational, retrospective, single center, not peer reviewed

**T Janowitz et al. Gut 2020**² *(added 6/5/2020)*  
**Population:** non-hospitalized patients (n=10)  
**Design:** case series; self-administered famotidine (80 mg tid x 11 days most commonly used)

### Adverse Effects/Interactions
- **Adverse Effects:**  
  - Hepatitis, hematologic toxicity, and CNS effects such as headache, lethargy, depression, and cognitive impairment have occurred
- **Drug Interactions:**  
  - May decrease serum concentrations of drugs that require gastric acidity for absorption

### Comments
- Mechanism not established; computer simulation suggested famotidine may inhibit an enzyme required for replication of the virus
- Concerns about use in patients with renal impairment (especially at high doses)

### Pregnancy
- No adequate data in pregnant women; no evidence of risk in animal studies
<table>
<thead>
<tr>
<th>DRUG AND DOSAGE</th>
<th>EFFICACY</th>
<th>ADVERSE EFFECTS/INTERACTIONS</th>
<th>COMMENTS</th>
</tr>
</thead>
</table>
| **FAMOTIDINE (continued)** | **Results:**  
- combined symptom score improved significantly within 24 hrs of famotidine  
- symptoms (cough, shortness of breath, fatigue, headache, anosmia) were scored on a 4-point ordinal scale  
- no patients were hospitalized  
- time from onset of symptoms to start of treatment ranged from 2 to 26 days  
**Limitations:** case series (small number of patients, no placebo group) | | |
| | **Mather et al. Am J Gastroenterol 2020** (added 8/19/2020)  
**Population:** hospitalized patients with COVID-19 at a single center in Connecticut (n=878; 83 received famotidine)  
**Design:** retrospective, propensity-matched observational study  
- compared patients receiving famotidine (PO or IV at any dose within 7 days of COVID screening or hospital admission) to those not receiving the drug  
**Results:**  
- patients treated with famotidine were younger than those who were not  
- famotidine use associated with decreased risk of in-hospital mortality (OR 0.37; 95% CI 0.16-0.86; p=0.021) | | |
<table>
<thead>
<tr>
<th>DRUG AND DOSAGE</th>
<th>EFFICACY</th>
<th>ADVERSE EFFECTS/INTERACTIONS</th>
<th>COMMENTS</th>
</tr>
</thead>
</table>
| FAMOTIDINE (continued) | - famotidine also associated with decreased risk of combined death or intubation and lower levels of serum markers for severe disease (CRP, procalcitonin, ferritin)  
**Limitations:** observational data  
**Hogan et al. Pulm Pharmacol Ther 2020** *(added 9/21/2020)*  
**Population:** hospitalized patients with COVID-19 treated with famotidine 20 mg bid and cimetidine 10 mg bid plus standard care (n=110)  
**Design:** retrospective cohort study  
**Results:** combination appeared to reduced symptom progression when compared to published reports of COVID-19 inpatients  
**Limitations:** retrospective data; not enough patients in control group for comparison | - | - | - |

<table>
<thead>
<tr>
<th>DRUG AND DOSAGE</th>
<th>EFFICACY</th>
<th>ADVERSE EFFECTS/INTERACTIONS</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Vitamins</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ASCORBIC ACID – GENERICS</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Dosage:</strong></td>
<td>▪ Optimal dosage not established</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>12 g IV q12h x 7 days (infused at a rate of 12 ml/hr)</td>
<td>▪ Trials in China and Italy of high-dose ascorbic acid in patients with severe COVID-19-associated pneumonia are ongoing</td>
<td>▪ Antioxidant properties may protect host cells against infection-induced oxidative stress; may boost host defenses against infection</td>
</tr>
<tr>
<td></td>
<td>▪ The results of these trials have not been published to date</td>
<td>▪ Adverse effects: ▪ Large doses can acidify the urine, causing cysteine, urate, or oxalate stones; prolonged administration of high IV doses can cause oxalate nephropathy</td>
<td>▪ Infection may reduce vitamin C concentrations</td>
</tr>
<tr>
<td></td>
<td></td>
<td>▪ Nausea, vomiting, diarrhea, dizziness, and flushing can occur</td>
<td>▪ In the CITRIS-ALI trials, a 50 mg/kg dose q6h x 4 days did not significantly improve organ dysfunction or inflammation markers in patients with sepsis and ARDS²</td>
</tr>
<tr>
<td></td>
<td></td>
<td>▪ Drug Interactions: ▪ May decrease serum concentrations of amphetamines</td>
<td>▪ NIH guidelines state there are insufficient data to recommend for or against use of vitamin C in non-critically ill patients or in critically ill patients³ (added 7/21/2020)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>▪ May decrease the efficacy of bortezomib (Velcade, and generics) and cyclosporine</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>▪ May cause deferoxamine (Desferal) toxicity and left ventricular dysfunction; avoid oral doses &gt;200 mg/day</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>▪ Pregnancy: ▪ No data are available in pregnant women</td>
<td></td>
</tr>
</tbody>
</table>
## DRUG AND DOSAGE

### ZINC – ZINC SULFATE

*(updated 7/21/2020)*

### Dosage:
- Optimal dosage not established
- 220 mg daily x 5 days
- Recommended dietary allowance: 11 mg/day for men and 8 mg/day for nonpregnant women

### Efficacy

**ADVERSE EFFECTS/INTERACTIONS**

### Adverse Effects:
- Bad taste and nausea
- Irreversible anosmia when administered intranasally
- GI symptoms have occurred with high doses
- Long-term use: copper deficiency leading to reversible hematologic (anemia, leukopenia) and neurologic adverse effects (myelopathy, paresthesia, ataxia, spasticity)

### Drug Interactions:
- Zinc can interfere with absorption of many drugs including fluoroquinolones

### Comments
- Impairs replication of some RNA viruses including SARS-CoV in vitro; no data on the activity of zinc against SARS-CoV-2
- Chloroquine/hydroxychloroquine may increase cellular uptake of zinc by SARS-CoV-2
- NIH guidelines state there is insufficient data to recommend for or against use or zinc; they recommend against use of doses above the recommended dietary allowance for prevention of COVID-19, except in a clinical trial *(added 7/21/2020)*
- Several trials are ongoing assessing the efficacy of zinc, some in combination with other vitamins, such as ascorbic acid, and/or drugs, such as hydroxychloroquine

### Pregnancy:
- Limited data on the safety of doses higher than the recommended daily allowance in pregnant women

---

1. Dosage regimen tried for treatment of covid-19; effective dosage has not been established in clinical trials.
### DRUG AND DOSAGE

**VITAMIN D**

**Dosage:**
- Dosage in patients with COVID-19 not established
- 400-800 IU/day (recommended daily allowance for most people)
- Serum 25(OH)D 20 to 30 ng/mL: 800-2000 IU/day
- Serum 25(OH)D <20 ng/mL: may need 50,000 IU/week

### EFFICACY

- Observational studies have suggested there is an association between vitamin D levels and severity of COVID-19 illness; people with vitamin D deficiency may be at higher risk of more severe disease.1,2,8
- Earlier meta-analysis of randomized trials in patients with respiratory tract infections (non-COVID-19) found vitamin D supplementation associated with reduced risk of respiratory tract infections.3
- Earlier randomized, double-blind trial of critically ill (non-COVID-19) patients found no significant effect of vitamin D administration on 90-day mortality vs placebo.4

### ADVERSE EFFECTS/INTERACTIONS

**Adverse Effects:**
- Excessive doses could cause toxicity (hypercalciuria, hypercalcemia, nausea, vomiting, anorexia, constipation, dehydration, fatigue, irritability, confusion, weakness)
- Metabolism of vitamin D altered in patients with chronic kidney disease

### COMMENTS

- Vitamin D plays an important role in immune function
- Limited data in COVID-19 and other serious illness
- NIH guidelines state there are insufficient data to recommend for or against use of vitamin D for prevention or treatment of COVID-197 (added 7/22/2020)
- NICE guidance states that there is no evidence to support use of vitamin D supplements to prevent or treat COVID-195 (added 6/30/2020)
- An expert consensus paper states that vitamin D supplements have not been shown to prevent or treat COVID-19 and strongly cautions against use of high doses of vitamin D; avoidance of vitamin D deficiency is recommended6 (added 6/17/2020)
- Some sources of vitamin D include exposure to sunlight, fortified cereals and dairy products, fatty fish

---


<table>
<thead>
<tr>
<th>DRUG AND DOSAGE</th>
<th>EFFICACY</th>
<th>ADVERSE EFFECTS/INTERACTIONS</th>
<th>COMMENTS</th>
</tr>
</thead>
</table>
| **THIAMINE**    | ▪ There are no published trials evaluating use of thiamine for treatment or prevention of COVID-19  
▪ One protocol that has not yet been evaluated in randomized controlled trials includes thiamine in addition to methylprednisolone, ascorbic acid, and heparin for treatment of hospitalized patients with COVID-19  
▪ In a retrospective study in (non-COVID) patients with septic shock, thiamine was associated with improved lactate clearance and reduced 28-day mortality compared to controls  
▪ In a randomized clinical trial of ICU patients (non-COVID), administration of an intervention consisting of IV vitamin C, hydrocortisone, and thiamine did not increase time alive or vasopressor free compared to hydrocortisone alone | ▪ Adverse Effects:  
▪ Thiamine is water-soluble and toxic levels are not expected | ▪ Thiamine deficiency has been reported to occur commonly in critically ill patients; evidence on whether thiamine use can improve mortality in critically ill (non-COVID) patients has been conflicting  
▪ There are no controlled trials evaluating use of thiamine in critically ill patients with COVID-19 |

**Dosage:**  
▪ Dosage in patients with COVID-19 not established  
▪ 200 mg IV q12h

---

<table>
<thead>
<tr>
<th>DRUG AND DOSAGE</th>
<th>EFFICACY</th>
<th>ADVERSE EFFECTS/INTERACTIONS</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>OTC Products</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nasal Saline Irrigation</td>
<td>▪ No data for treatment or prevention of COVID-19</td>
<td>▪ Minor nasal discomfort or irritation</td>
<td>▪ No evidence that regular nasal saline irrigation can prevent or treat COVID-19 infection</td>
</tr>
<tr>
<td></td>
<td>▪ Open-label, randomized trial in 61 patients with viral upper respiratory tract infections (including rhinovirus and coronavirus), hypertonic nasal saline irrigation shortened the duration of illness, lowered transmission to household contacts, and reduced viral shedding¹</td>
<td>▪ Sterile, distilled, or boiled (and cooled) tap water should be used to prevent bacterial or protozoal infection²</td>
<td>▪ Some limited evidence that nasal irrigation with hypertonic saline can shorten the duration of the common cold</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>▪ Hypothesized mechanism is cellular use of chloride ions to produce hypochlorous acid (HOCL), which has antiviral effects¹</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Melatonin</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MELATONIN – GENERICS</td>
<td>▪ No data available on use of melatonin for treatment of COVID-19</td>
<td>▪ Well tolerated; dizziness, headache, nausea, and sleepiness can occur</td>
<td>▪ May have anti-viral and anti-inflammatory effects; could decrease serum levels of inflammatory cytokines</td>
</tr>
<tr>
<td>Dosage:</td>
<td>▪ Optimal dosage not established</td>
<td>▪ May decrease the antihypertensive effects of calcium channel blockers</td>
<td>▪ Has been used in critical care patients (not COVID-19) to reduce vessel permeability, anxiety, sedation use, and improving sleeping quality²</td>
</tr>
<tr>
<td></td>
<td>5-10 mg/day PO¹</td>
<td>▪ Melatonin is a substrate of CYP1A2; inducers of CYP1A2 may decrease melatonin concentrations and inhibitors of CYP1A2 may increase melatonin concentrations³</td>
<td>▪ Pregnancy:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>▪ Limited data on the safety of melatonin use during pregnancy</td>
</tr>
<tr>
<td>DRUG AND DOSAGE</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----------------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Benzalkonium Chloride</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>BENZALKONIUM CHLORIDE</th>
</tr>
</thead>
<tbody>
<tr>
<td>(added 5/9/2020)</td>
</tr>
</tbody>
</table>

**Dosage:**
- Topical use
- Available OTC in hand sanitizer formulations and an intranasal formulation

**Efficacy:**
- The manufacturer of a nasal formulation of 0.13% benzalkonium chloride (*NanoBio Protect*) states the product has been shown to kill SARS-CoV-2 in *in vitro* studies conducted by Public Health England; published data are not yet available.\(^1\)

Previous studies have reported that 0.05-0.2% benzalkonium chloride formulations were less effective than alcohol-based disinfectants against other coronaviruses.

**Adverse Effects:**
- Irritation, burning or stinging, hypersensitivity reactions

**Adverse Effects/Interactions:**
- No clinical data demonstrating efficacy of a nasal formulation of benzalkonium chloride for prevention of COVID-19 infection
- The CDC recommends alcohol-based hand sanitizers containing 80% ethanol or 75% isopropanol.\(^3\)

---

### Renin-Angiotensin System (RAS) Inhibitors

<table>
<thead>
<tr>
<th>DRUG</th>
<th>CONCERNS/MECHANISM</th>
<th>CLINICAL STUDIES</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS (updated 9/1/2020)</strong></td>
<td>Increased risk of severe COVID-19 in patients with cardiovascular disease</td>
<td>P Zhang et al. Circ Res 2020⁴</td>
<td>Multiple medical organizations, including the NIH, have advised against stopping or starting these drugs to prevent or treat COVID-19 infection³,10,11</td>
</tr>
<tr>
<td>Benazepril (Lotensin, and generics)</td>
<td>ACE inhibitors and ARBs increase expression of ACE2 by epithelial cells in the lung, and pathogenic coronaviruses such as SARS-CoV-2 enter these cells via ACE2 receptors¹</td>
<td>Population: hospitalized patients w/ hypertension (n=1128)</td>
<td>Patients who are taking an ACE inhibitor or an ARB and subsequently develop COVID-19 should continue to take the drug³,10</td>
</tr>
<tr>
<td>Captopril (generic)</td>
<td>Some researchers have suggested that this increase in risk may be due to use of ACE inhibitors or ARBs in patients with diabetes, hypertension, or heart failure</td>
<td>188 taking an ACE inhibitor or ARB</td>
<td>Some evidence from retrospective trials suggesting that use of an ACE inhibitor or an ARB in patients with hypertension who were hospitalized for COVID-19 was associated with similar or lower mortality rates compared to patients who were not taking a drug from either class prior to infection.⁴,⁵,⁶</td>
</tr>
<tr>
<td>Enalapril (Vasotec, and others)</td>
<td>Others have suggested, however, that ACE2 may protect against lung injury in coronavirus infection and that taking an ACE inhibitor or an ARB might be beneficial²,³</td>
<td>Design: retrospective, multi-center</td>
<td>Prospective randomized-controlled trials evaluating these drugs in patients hospitalized for COVID-19 are in progress¹⁶</td>
</tr>
<tr>
<td>Fosinopril (generic)</td>
<td>Population: hospitalized patients w/ hypertension (n=1178); 362 patients with hypertension, 115 taking an ACE inhibitor or ARB</td>
<td>Results: percentage of patients taking an ACE inhibitor or ARB was similar between patients with (32.9%) and without (30.7%) severe infection and between survivors (33.0%) and non-survivors (27.3%)</td>
<td></td>
</tr>
<tr>
<td>Lisinopril (Zestril, Prinivil, and others)</td>
<td>Design: retrospective, single-center</td>
<td>Results: adjusted HR 0.37 (95% CI, 0.15-0.89; P = 0.03) in a propensity score-matched analysis</td>
<td></td>
</tr>
<tr>
<td>Moexipril (generic)</td>
<td>Population: hospitalized patients (n = 1118); 362 patients with hypertension, 115 taking an ACE inhibitor or ARB</td>
<td>Limitations: no adjustment for confounding factors</td>
<td></td>
</tr>
<tr>
<td>Perindopril (generic)</td>
<td>Design: retrospective</td>
<td>Limitations: retrospective</td>
<td></td>
</tr>
<tr>
<td>Quinapril (Accupril, and generics)</td>
<td>Results: all-cause mortality was lower in patients taking an ACE inhibitor or ARB compared to those not taking an ACE inhibitor or ARB (3.7% vs 9.8%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ramipril (Altace, and generics)</td>
<td>Limitations: retrospective</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trandolapril (generic)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

**ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)**

<p>| Azilsartan (Edarbi) | Increased risk of severe COVID-19 in patients with cardiovascular disease | J Li et al. JAMA Cardiol 2020⁵ | |
| Candesartan (Atacand, and generics) | ACE inhibitors and ARBs increase expression of ACE2 by epithelial cells in the lung, and pathogenic coronaviruses such as SARS-CoV-2 enter these cells via ACE2 receptors¹ | Population: hospitalized patients (n = 1178); 362 patients with hypertension, 115 taking an ACE inhibitor or ARB | |
| Eprosartan (Teveten and generics) | Some researchers have suggested that this increase in risk may be due to use of ACE inhibitors or ARBs in patients with diabetes, hypertension, or heart failure | Design: retrospective, single-center | |
| Irbesartan (Avapro, and generics) | Others have suggested, however, that ACE2 may protect against lung injury in coronavirus infection and that taking an ACE inhibitor or an ARB might be beneficial²,³ | Results: percentage of patients taking an ACE inhibitor or ARB was similar between patients with (32.9%) and without (30.7%) severe infection and between survivors (33.0%) and non-survivors (27.3%) | |
| Losartan (Cozaar, and generics) | Population: hospitalized patients (n = 1128) | Results: adjusted HR 0.37 (95% CI, 0.15-0.89; P = 0.03) in a propensity score-matched analysis | |
| Olmesartan (Benicar, and generics) | Design: retrospective | Limitations: retrospective | |
| Telmisartan (Micardis, and generics) | Results: all-cause mortality was lower in patients taking an ACE inhibitor or ARB compared to those not taking an ACE inhibitor or ARB (3.7% vs 9.8%) | Limitations: no adjustment for confounding factors | |</p>
<table>
<thead>
<tr>
<th>DRUG</th>
<th>CONCERNS/MECHANISM</th>
<th>CLINICAL STUDIES</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Valsartan (<em>Diovan</em>, and generics)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- **DM Bean et al. 2020**
  - **Population:** hospitalized patients (n=205)
  - **Design:** retrospective, single-center
  - **Results:** Lower rate of death or transfer to the ICU within 7 days of symptom onset in patients on an ACE inhibitor (OR 0.29)
  - **Limitations:** small sample size, not peer reviewed

- **Mancia et al. NEJM 2020**
  - **Population:** 6272 case patients with COVID-19; 30,759 controls
  - **Design:** population-based case-control study in Italy
  - **Results:**
    - use of ACE inhibitors or ARBs was not associated with COVID-19 among case patients (adjusted OR for ACE inhibitors 0.96 [CI 0.87-1.07] and for ARBs 0.95 [CI 0.86-1.05])
    - no association between use of ACE inhibitors or ARBs and severe or fatal disease (adjusted OR for ACE inhibitors 0.91 [CI 0.69-1.21] and for ARBs 0.83 [CI 0.63-1.10])
  - **Limitations:** observational data

- **Mehra et al. NEJM 2020** *(updated 6/4/2020)*
  - **Study Retracted***
    - Retracted because of concerns about the accuracy of the data and analysis; an independent audit was not possible because the full dataset was not made available
  - **Population:** 8910 hospitalized patients in Asia, Europe, and North America
  - **Design:** observational; data collected from an international registry

- A review of multiple trials of ACEI or ARB use in patients with COVID-19 concluded there is high-certainty evidence that use of these drugs is not associated with more severe disease *(added 7/28/2020)*
ACE INHIBITORS AND ARBS (CONTINUED)

<table>
<thead>
<tr>
<th>DRUG</th>
<th>CONCERNS/MECHANISM</th>
<th>CLINICAL STUDIES</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Results: Use of ACE inhibitors or ARBs was not found to be associated with an increased risk of in-hospital death</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Limitations: observational data</td>
<td></td>
</tr>
<tr>
<td><strong>Reynolds et al. NEJM 2020⁹</strong></td>
<td></td>
<td><strong>Population:</strong> 12,954 patients tested for COVID-19 in a New York City health system</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Design:</strong> observational; data obtained from electronic medical records</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Results:</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>▪ 5894 (46.8%) were positive; 1002 of them (17.0%) had severe illness</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>▪ ACE inhibitors, ARBs, or other antihypertensive drug classes (beta-blockers, calcium channel blockers, thiazide diuretics) were not associated with an increased risk of COVID-19 infection or of severe illness</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Limitations:</strong> observational data</td>
<td></td>
</tr>
<tr>
<td><strong>Flacco et al. Heart 2020¹³ (added 7/15/2020)</strong></td>
<td></td>
<td><strong>Population:</strong> 9890 hypertensive patients treated with ACE inhibitors, ARBs, or both vs untreated patients</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Design:</strong> meta-analysis of observational data from 10 cohort or case-control studies comparing risk of severe/fatal COVID-19 in patients treated with ACE inhibitors/ARBs vs untreated patients</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Results:</strong> The risk of severe/fatal COVID-19 was similar between patients treated with ACE inhibitors/ARBs and untreated patients (OR 0.90, 95% CI 0.65 to 1.26 for ACE inhibitors; OR 0.92, 95% CI 0.75 to 1.12 for ARBs)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Limitations:</strong> meta-analysis of observational data; intermediate-to-high level of heterogeneity</td>
<td></td>
</tr>
</tbody>
</table>
### ACE INHIBITORS AND ARBS (CONTINUED)

<table>
<thead>
<tr>
<th>DRUG</th>
<th>CONCERNS/MECHANISM</th>
<th>CLINICAL STUDIES</th>
<th>COMMENTS</th>
</tr>
</thead>
</table>
|      |                   | **Fosbøl et al. JAMA 2020**<sup>14</sup>  
*added 7/28/2020*  
**Population:** Retrospective Cohort Study:  
- hypertensive patients with COVID-19  
  (n=4480)  
**Nested, Case-Control:**  
- Cases (COVID-19, prior hypertension; n=571);  
  controls (no COVID-19, prior hypertension; n=5710)  
**Design:** retrospective cohort study examining outcomes in patients with COVID-19; nested, case-control design for susceptibility analysis; from Danish registry  
**Results:**  
**Retrospective Cohort Study: ACEI/ARB use vs no use**  
- Mortality within 30 days was 18.1% in the ACEI/ARB group compared to 7.3% in the nonuser group (significant difference in unadjusted analysis; not statistically significant after adjustment for age, sex, and medical history)  
- Death or severe COVID-19 occurred in 31.9% of ACEI/ARB users and 14.2% of nonusers by 30 days (significant difference in unadjusted analysis; not statistically significant after adjustment)  
**Nested Case-Control Susceptibility Analysis:**  
**ACEI/ARB use vs other hypertensive drugs**  
- ACEI/ARB use was not associated with a higher incidence of COVID-19, compared with use of other antihypertensives  
**Limitations:** retrospective data |
<table>
<thead>
<tr>
<th>DRUG</th>
<th>CONCERNS/MECHANISM</th>
<th>CLINICAL STUDIES</th>
<th>COMMENTS</th>
</tr>
</thead>
</table>
| ACE INHIBITORS AND ARBS (CONTINUED) |                    | **Felice et al. Am J Hypertens 2020**<sup>15</sup>  
(added 7/28/2020) | **Population:** consecutive hypertensive patients presenting to ER in Italy with acute respiratory symptoms and/or fever or diagnosis of COVID-19 (n=133)  
**Design:** single center, retrospective study  
**Results:** rate of admission to semi-intensive/intensive care units was lower patients treated with ACEIs or ARBs, compared to patients not treated with ACEIs or ARBs  
**Limitations:** small retrospective study |
|                      |                    | **Selçuk et al. Clin Exp Hypertens 2020**<sup>18</sup>  
(added 7/28/2020) | **Population:** consecutive hypertensive patients hospitalized for COVID-19 in Turkey (n=113)  
**Design:** retrospective study  
**Results:**  
- Patients in the ACEI/ARB group were older and were more likely to have coronary artery disease than those taking other antihypertensives  
- Use of an ACEI or ARB was associated with a higher frequency of admission to the ICU, endotracheal intubation, and death compared with other antihypertensives  
**Limitations:** small retrospective study; patients on ACEIs/ARBs more likely to have coronary artery disease and were older |
|                      |                    | **Lopes et al. BRACE CORONA Trial**  
(Presented at ESC Sept 1, 2020) | **Population:** hospitalized for mild-moderate COVID-19 who were taking an ACEI or ARB on admission (n=659)  
**Design:** randomized trial |

- 83 -
<table>
<thead>
<tr>
<th>DRUG</th>
<th>CONCERNS/MECHANISM</th>
<th>CLINICAL STUDIES</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Results: No significant difference between those who stopped taking the ACEI or ARB and those who continued taking it. Number of days alive and out of hospital 21.9 in those who stopped vs 22.9 in those who continued.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>DRUG</th>
<th>CONCERNS/MECHANISM</th>
<th>CLINICAL STUDIES</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nonsteroidal Anti-inflammatory Drugs (NSAIDs)</td>
<td>▪ The Health Minister of France has warned that use of NSAIDs such as ibuprofen (Advil, Motrin, and others) to reduce fever in patients with COVID-19 increases the risk of severe adverse events and recommended use of acetaminophen (Tylenol, and others) instead&lt;sup&gt;1&lt;/sup&gt;</td>
<td>▪ No convincing evidence that NSAIDs are especially dangerous for patients with COVID-19&lt;sup&gt;2&lt;/sup&gt;, but they can cause GI bleeding, fluid retention, and renal dysfunction in any patient, which can be dangerous for the critically ill&lt;br&gt; ▪ Acetaminophen is an effective antipyretic alternative to an NSAID and in recommended doses is less likely than an NSAID to cause serious adverse effects in most patients</td>
<td>▪ Use of an NSAID or acetaminophen for continual fever suppression may reduce the immune response and prolong viral shedding&lt;br&gt; ▪ NIH guidelines recommend that antipyretic strategies (e.g., with acetaminophen or NSAIDs) should not differ between patients with or without COVID-19&lt;sup&gt;3&lt;/sup&gt;&lt;br&gt; ▪ Patients who are taking NSAIDs for other indications should not stop taking them&lt;sup&gt;3&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>DRUG</th>
<th>CONCERNS/MECHANISM</th>
<th>CLINICAL STUDIES</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Proton Pump Inhibitors (PPIs)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>PROTON PUMP INHIBITORS (PPIs)</strong></td>
<td>▪ PPI use may increase the risk of COVID-19</td>
<td><strong>Almario Gastroenterology 2020</strong>&lt;sup&gt;2&lt;/sup&gt; &lt;br&gt; Population: English-speaking adults in the US (n=53,130) &lt;br&gt; Design: online population-based survey</td>
<td>▪ No randomized controlled trials</td>
</tr>
<tr>
<td>▪ Dexlansoprazole (Dexilant)</td>
<td>▪ PPIs increase gastric pH and have been associated with an increased risk of enteric infections&lt;sup&gt;1&lt;/sup&gt;</td>
<td>▪ Survey included questions about PPI and/or H2-receptor antagonist use and positive test results for COVID-19</td>
<td>▪ Twice-daily PPI use was associated with higher risk than once-daily use in an observational trial&lt;sup&gt;2&lt;/sup&gt;</td>
</tr>
<tr>
<td>▪ Esomeprazole magnesium (Nexium, Nexium 24HR, and generics)</td>
<td>▪ SARS-CoV-1 is impaired at a pH of 3 or below; it is possible that pH has a similar effect on SARS-CoV-2</td>
<td>▪ Use of H2-receptor antagonists was not associated with an increased risk of COVID-19</td>
<td>▪ American College of Gastroenterology (ACG) recommends use of the lowest effective dose of PPIs in patients with a clinical indication for their use&lt;sup&gt;1&lt;/sup&gt;</td>
</tr>
<tr>
<td>▪ Lansoprazole (Prevacid, Prevacid 24HR, and generics)</td>
<td>▪ Theoretically, higher gastric pH may allow viral replication in the gut; SARS-CoV-2 enters cells via ACE-2 receptors, which are widely expressed in the GI tract&lt;sup&gt;1&lt;/sup&gt;</td>
<td>▪ Results:</td>
<td></td>
</tr>
<tr>
<td>▪ Omeprazole (Prilosec, Prilosec OTC, and generics)</td>
<td></td>
<td>▪ Twice-daily PPI use was associated with a 3.7-fold increased odds of COVID-19 and once-daily PPI use was associated with a 2.2-fold increase, compared to no PPI use</td>
<td></td>
</tr>
<tr>
<td>▪ Omeprazole/sodium bicarbonate (Zegerid, Zegerid OTC, and generics)</td>
<td></td>
<td>▪ Use of H2-receptor antagonists was not associated with an increased risk of COVID-19</td>
<td></td>
</tr>
<tr>
<td>▪ Pantoprazole (Protonix, and generics)</td>
<td></td>
<td>▪ Limitations: observational data, patients taking PPIs may have more underlying risk factors than those not on PPIs</td>
<td></td>
</tr>
<tr>
<td>▪ Rabeprazole (Aciphex, and generics)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---


<table>
<thead>
<tr>
<th>DRUG</th>
<th>CONCERNS/MECHANISM</th>
<th>CLINICAL STUDIES</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biguanide</td>
<td>▪ Metformin associated with reduced risk of death from COVID-19 in patients with type 2 diabetes in observational studies&lt;sup&gt;1&lt;/sup&gt;</td>
<td>▪ <strong>Crouse et al MedRxiv 2020</strong>&lt;sup&gt;2&lt;/sup&gt;</td>
<td>▪ No randomized controlled trials</td>
</tr>
<tr>
<td>METFORMIN</td>
<td>▪ Mechanism not established, but may be associated with effects of metformin on glucose control, body weight, and insulin resistance, anti-inflammatory effects of metformin, and decreased viral entry due to effects of metformin on ACE2&lt;sup&gt;1&lt;/sup&gt;</td>
<td><strong>Population:</strong> hospitalized patients tested for COVID-19 at a single hospital in the Southern US (n=25,326)</td>
<td>▪ Diabetes is a risk factor for severe COVID-19 illness and death</td>
</tr>
<tr>
<td></td>
<td>▪ Potential risk of lactic acidosis in hospitalized COVID-19 patients with multiple organ failure</td>
<td><strong>Design:</strong> retrospective review of electronic health records</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Results:</strong> in patients with diabetes and COVID-19, metformin was associated with a significant reduction in mortality (OR 0.33; 95% CI 0.13-0.84; p=0.0210)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Limitations:</strong> not peer reviewed, observational data, possible confounders</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Bramante et al. MedRxiv 2020</strong>&lt;sup&gt;3&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Population:</strong> hospitalized patients with COVID-19 (n=6,256)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Design:</strong> retrospective review of records from a large health insurance organization</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Results:</strong> metformin was associated with a decreased risk of mortality in women (OR 0.792; 95% CI 0.640-0.979)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Limitations:</strong> not peer reviewed, observational data, possible confounders</td>
<td></td>
</tr>
</tbody>
</table>

---

## CHIMPANZEE ADENOVIRUS-VECTORED COVID-19 (ChAdOx1 nCoV-19) VACCINE (AZD1222)

**(AstraZeneca/Oxford)**

*(updated 9/24/2020)*

**Population:** healthy adults 18-55 years old in the UK (n=1077)

**Design:** phase 1/2, single-blind, multicenter, randomized controlled trial

- participants randomized to 1 dose of ChAdOx1 nCoV-19 vaccine or a comparator meningococcal conjugate vaccine (MenACWY)

**Results:**

- >90% of participants developed neutralizing antibodies; in 10 patients who received a booster dose, 100% had neutralizing antibodies
- Increases in SARS-CoV-2 spike-specific effector T-cell responses occurred by day 7, peaked at day 14, and were maintained up to day 56
- Local and systemic adverse effects were common

**Limitations:** preliminary results of phase 1/2 trial

**Efficacy**

**Folegatti et al. Lancet 2020**

- Common adverse effects in the phase 1/2 trial included injection-site pain (67%) and tenderness (83%), fatigue (70%), headache (68%), muscle ache (60%), malaise (61%), chills (56%), feeling feverish (51%), fever (18%)
- Use of acetaminophen reduced adverse effects
- Transient neutropenia was reported in 46%

**Safety**

- A participant in one of the ongoing phase 3 trials in the UK experienced a serious neurologic adverse reaction, which has been reported to possibly be transverse myelitis; whether the adverse reaction was caused by the vaccine is under investigation *(added 9/18/2020)*

**Comments**

- Chimpanzee adenovirus- vectored vaccine expressing the SARS-CoV-2 spike protein
- Demonstrated immunogenicity in a phase 1/2 trial
- Phase 2/3 trials ongoing in several countries including the US
- Manufacturer may be able to deliver emergency doses of the vaccine by fall 2020
- Phase 3 trials temporarily halted due to a serious neurologic adverse reaction in a participant in the UK who received the vaccine; the UK trial has been restarted after review by the Medicines Health Regulatory Authority (MHRA); a trial in the US is still on hold *(added 9/18/2020)*
- Two-dose vaccine (4 weeks apart)

- Refrigeration required for vaccine storage
RECOMBINANT ADENOVIRUS TYPE-5 (Ad5)-VECTORED COVID-19 VACCINE
(CanSino Biologics)
(updated 9/23/2020)

<table>
<thead>
<tr>
<th>VACCINE</th>
<th>EFFICACY</th>
<th>SAFETY</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zhu et al. Lancet 2020²</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Population: healthy adults &gt;18 years old (n=508)</td>
<td></td>
<td>The most common adverse effects in the phase 2 trial were injection-site pain (56-57%), fatigue (34-42%), fever (16-32%), and headache (28-29%)</td>
<td>Non-replicating adenovirus type-5 (Ad5)-vectored COVID-19 vaccine</td>
</tr>
<tr>
<td>Design: phase 2, randomized, double-blind, placebo-controlled trial</td>
<td></td>
<td>No serious adverse events were reported</td>
<td>Contained replication-defective Ad5 vectors expressing the full-length spike gene based on Wuhan-Hu-1</td>
</tr>
<tr>
<td>Participants randomized to 1 dose of vaccine with 1x10¹¹ viral particles/mL or 5x10¹⁰ viral particles/mL or to placebo</td>
<td></td>
<td></td>
<td>Possibly lower responses in people with pre-existing immunity to the vector and in those &gt;55 years old</td>
</tr>
<tr>
<td>Results:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>▪ Seroconversion rates were &gt;96%</td>
<td></td>
<td></td>
<td>In earlier trials, Ad5-vectored vaccines were not effective for prevention of HIV; in one trial, the incidence of HIV was higher in the vaccinated group than the placebo group (added 9/23/2020)</td>
</tr>
<tr>
<td>▪ &gt;90% had T-cell responses</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>▪ antibody responses were lower in participants &gt;55 years old and in those with previous vector immunity</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>▪ local and systemic adverse reactions were common</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Limitations: phase 2 data; possible lack of power to show a difference between dose groups</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>


- 89 -
<table>
<thead>
<tr>
<th>VACCINE</th>
<th>EFFICACY</th>
<th>SAFETY</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>▪ Phase 1/2a human trials started in July</td>
<td></td>
<td>▪ Ad26 technology used in the manufacturer’s Ebola vaccine recently approved by the European Commission</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>▪ Phase 3 trial has started; expected to enroll up to 60,000 participants^2,3 (updated 9/23/2020)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>▪ Single-dose vaccine</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>▪ Refrigeration required for storage</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>VACCINE</th>
<th>EFFICACY</th>
<th>SAFETY</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>mRNA Vaccines</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>mRNA-1273 (Moderna) (&lt;updated 7/30/2020&gt;)</td>
<td><strong>Jackson et al. NEJM 2020</strong>¹&lt;br&gt;&lt;br&gt;<strong>Population:</strong> healthy adults 18-55 years old (n=45) &lt;br&gt;&lt;br&gt;<strong>Design:</strong> phase 1, dose-escalation, open-label trial  &lt;br&gt;▪ 2 vaccinations delivered 28 days apart at a 25 mcg, 100 mcg, or 250 mcg dose&lt;br&gt;&lt;br&gt;<strong>Results:</strong>  &lt;br&gt;▪ antibody responses higher with the higher dose after 1st vaccination &lt;br&gt;▪ serum-neutralizing activity detected after 2nd vaccination in all participants &lt;br&gt;&lt;br&gt;<strong>Limitations:</strong> preliminary results from a phase 1 trial</td>
<td>▪ Fatigue, chills, headache, myalgia, and pain at the injection site reported in the phase 1 trial &lt;br&gt;&lt;br&gt;▪ Systemic adverse events more common after 2nd vaccination &lt;br&gt;&lt;br&gt;▪ No serious adverse events reported</td>
<td>▪ Lipid nanoparticle-encapsulated, nucleoside-modified messenger RNA (mRNA)-based vaccine &lt;br&gt;&lt;br&gt;▪ Encodes the SARS-CoV2 spike (S) glycoprotein, which is needed for host cell attachment and viral entry &lt;br&gt;&lt;br&gt;▪ FDA granted fast track designation &lt;br&gt;&lt;br&gt;▪ Reduced viral replication in the lungs and noses of primates (KS Corbett et al. NEJM 2020)² &lt;br&gt;&lt;br&gt;▪ Phase 3 trial has begun; expected to enroll about 30,000 participants and use a dose of 100 mcg &lt;br&gt;&lt;br&gt;▪ Two-dose vaccine (28 days apart) &lt;br&gt;&lt;br&gt;▪ Ultra-cold freezer conditions (-4°F/-20°C) required for vaccine storage; can be stored under refrigeration for 1 week</td>
</tr>
<tr>
<td>BNT162b1 and BNT162b2 (Pfizer/BioNTech) (&lt;updated 9/18/2020&gt;)</td>
<td><strong>Mulligan et al. 2020</strong>³&lt;br&gt;&lt;br&gt;<strong>Population:</strong> healthy adults 18-55 years old (n=45) &lt;br&gt;&lt;br&gt;<strong>Design:</strong> phase 1/2 randomized, placebo-controlled, observer-blinded dose escalation study &lt;br&gt;▪ 2 doses separated by 21 days of 10 mcg, 30 mcg, or 100 mcg of BNT162b1 or placebo&lt;br&gt;&lt;br&gt;<strong>Results:</strong> &lt;br&gt;▪ At day 28, all subjects in the 10- and 30-mcg groups had significantly elevated RBD-binding IgG antibodies and neutralizing antibodies &lt;br&gt;&lt;br&gt;<strong>Limitations:</strong> phase 1/2 results</td>
<td>▪ The most common adverse effects in the phase 2 trial were injection-site pain (58.3-100%), fatigue, and headache &lt;br&gt;&lt;br&gt;▪ Fever, chills, muscle pain, and joint pain were also reported &lt;br&gt;&lt;br&gt;▪ No serious adverse events reported</td>
<td>▪ Both are lipid nanoparticle-formulated, nucleoside modified mRNA vaccines &lt;br&gt;&lt;br&gt;▪ BNT162b1 encodes an optimized SARS-CoV-2 receptor-binding domain (RBD) antigen &lt;br&gt;&lt;br&gt;▪ BNT162b2 encodes an optimized SARS-CoV-2 full-length spike protein antigen &lt;br&gt;&lt;br&gt;▪ FDA granted fast track designation</td>
</tr>
</tbody>
</table>
## BNT162b1 and BNT162b2 (continued)

<table>
<thead>
<tr>
<th><strong>VACCINE</strong></th>
<th><strong>EFFICACY</strong></th>
<th><strong>SAFETY</strong></th>
<th><strong>COMMENTS</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>Walsh et al. MedRxiv 2020</strong> <em>(added 8/23/2020)</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Population:</strong> healthy adults 18-55 and 65-85 years old (n=131)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Design:</strong> phase 1, randomized, observer-blinded, placebo-controlled trial</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>▪ 2 vaccinations delivered 21 days apart of 1 of 3 doses of BNT162b1 or BNT162b2 or placebo</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Results:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>▪ In 65-85-year old subjects, SARS-CoV-2-neutralizing geometric mean titers (GMTs) were 1.1-1.6 times the convalescent serum panel GMTs 7 days after the second dose</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>▪ In 18-55-year old subjects, neutralizing GMTs were 2.8-3.8 times the convalescent serum panel GMTs</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>▪ Antibody responses were similar between BNT162b1 and BNT162b2</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>▪ Systemic adverse events were milder with BNT162b2 than with BNT162b1</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Limitations:</strong> preliminary results from a phase 1 trial; not peer reviewed</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>In the ongoing phase 3 trial, the manufacturer has reported mostly mild to moderate adverse reactions (fatigue and headache have been most common); severe or grade 4 reactions have been rare</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>The manufacturer advanced BNT162b2 to phase 2/3 clinical trials based on data from phase 1 trials indicating it caused fewer adverse events than BNT162b1</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Phase 3 trial has begun; expected to enroll up to 30,000 participants; manufacturer submitted to FDA to increase to 44,000 participants <em>(updated 9/18/2020)</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Two-dose vaccine (21 days apart)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ultra-cold (-94° F/-70° C) freezer conditions required for vaccine storage; can only be stored under refrigeration for 24 hours</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

2. KS Corbett et al. Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates.
<table>
<thead>
<tr>
<th>VACCINE</th>
<th>EFFICACY</th>
<th>SAFETY</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Adjuvanted Recombinant Nanoparticle Vaccine</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NVX-CoV2373</td>
<td>Keech et al. NEJM 2020 <em>(updated 9/20/2020)</em></td>
<td>▪ Tenderness and pain at the injection site</td>
<td>▪ Recombinant nanoparticle vaccine composed of trimeric full-length SARS-CoV-2 spike glycoproteins²</td>
</tr>
<tr>
<td>(Novavax)</td>
<td>(updated 9/20/2020)</td>
<td>▪ Headache, fatigue, myalgia</td>
<td>▪ Contains saponin-based Matrix-M adjuvant</td>
</tr>
<tr>
<td></td>
<td>Population: healthy adults 18-59 years old (n=131)</td>
<td>▪ No serious adverse events reported</td>
<td>▪ Phase 2b trial ongoing in South Africa</td>
</tr>
<tr>
<td></td>
<td>Design: phase 1/2, randomized, observer-blinded, placebo-controlled trial</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>▪ 2 vaccinations (5 or 25 mcg) given 21 days apart with or without Matrix-M1 adjuvant or placebo</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Results:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>▪ The adjuvanted vaccine induced neutralizing antibody responses and antigen-specific T cells</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>▪ Neutralizing antibody responses after the second vaccination exceeded levels in COVID-29 convalescent serum</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Limitations: phase 1/2 trial</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Efficacy</th>
<th>Safety</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inactivated Vaccine</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| Whole-Virus Inactivated SARS-CoV-2 Vaccine (WIV04 strain) (Sinopharm) (added 8/21/2020) | **Xia et al. JAMA 2020**<sup>1</sup>  
**Population:** healthy adults 18-59 years old in China (phase 1 trial n=96; phase 2 trial n=224)  
**Design:** randomized, double-blind, placebo-controlled phase 1 and 2 trials  
  - **Phase 1:** 3 injections at day 0, 28, and 56 of a 2.5, 5, or 10 mcg vaccine or aluminum hydroxide adjuvant only  
  - **Phase 2:** 5 mcg vaccine at days 0 and 14, 5 mcg vaccine at days 0 and 21, or aluminum hydroxide adjuvant only  
**Results:**  
  - Neutralizing antibodies reported in all dose groups 14 days after completion of 3 injections in phase 1 and 2 injections in phase 2  
  - 100% seroconversion in patients in the phase 1 trial and in those who received injections on days 0 and 21 in phase 2  
  - Antibody titers increased after second and third injections  
**Limitations:** phase 1/2 interim data; did not use comparator group of convalescent serum samples | **Pain at the injection site, fever**  
**No serious adverse events reported** | **Whole-virus inactivated vaccine**  
**Phase 3 trial enrolling 15,000 volunteers started in Abu Dhabi in July** |

---
